Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,21.0,816,DB00435,Nitric Oxide
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,19.1,817,DB00435,Nitric Oxide
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,19,818,DB00435,Nitric Oxide
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],269,819,DB00435,Nitric Oxide
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],259,820,DB00435,Nitric Oxide
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],254,821,DB00435,Nitric Oxide
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],"1,187",822,DB00435,Nitric Oxide
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],"1,186",823,DB00435,Nitric Oxide
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],730,824,DB00435,Nitric Oxide
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],697,825,DB00435,Nitric Oxide
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],645,826,DB00435,Nitric Oxide
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],508,827,DB00435,Nitric Oxide
,19034869,NOx,"Application of a total of 19 mg/kg BH4 intravenously (i.v.) over 3 hours led to a dose-dependent increase in serum cGMP concentrations from a median 3.3 nM (interquartile range [IQR] 1.1-5.6) to 5.7 nM (IQR 2.4-13.3, p=0.008) and NOx from a median 49.3 microM (IQR 39.8-56.6) to 59.7 microM (39.6-85.5) (p=0.058).",Effects of tetrahydrobiopterin on nitric oxide bioavailability and renal hemodynamics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034869/),μM,49.3,973,DB00435,Nitric Oxide
,19034869,NOx,"Application of a total of 19 mg/kg BH4 intravenously (i.v.) over 3 hours led to a dose-dependent increase in serum cGMP concentrations from a median 3.3 nM (interquartile range [IQR] 1.1-5.6) to 5.7 nM (IQR 2.4-13.3, p=0.008) and NOx from a median 49.3 microM (IQR 39.8-56.6) to 59.7 microM (39.6-85.5) (p=0.058).",Effects of tetrahydrobiopterin on nitric oxide bioavailability and renal hemodynamics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034869/),μM,59.7,974,DB00435,Nitric Oxide
,29693578,IC50,"Besides, the IC50 for TCE, imperatorin and isoimperatorin inhibiting ligustrazine metabolism were 5.0 ± 1.02, 1.35 ± 0.46, 4.81 ± 1.14 µg/mL in human liver microsomes, and 13.69 ± 1.11, 1.19 ± 1.09, 1.69 ± 1.17 µg/mL in rat liver microsomes, respectively.",A Metabolism-Based Synergy for Total Coumarin Extract of Radix Angelicae Dahuricae and Ligustrazine on Migraine Treatment in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29693578/),[μg] / [ml],5.0,2202,DB00435,Nitric Oxide
,29693578,IC50,"Besides, the IC50 for TCE, imperatorin and isoimperatorin inhibiting ligustrazine metabolism were 5.0 ± 1.02, 1.35 ± 0.46, 4.81 ± 1.14 µg/mL in human liver microsomes, and 13.69 ± 1.11, 1.19 ± 1.09, 1.69 ± 1.17 µg/mL in rat liver microsomes, respectively.",A Metabolism-Based Synergy for Total Coumarin Extract of Radix Angelicae Dahuricae and Ligustrazine on Migraine Treatment in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29693578/),[μg] / [ml],1.35,2203,DB00435,Nitric Oxide
,29693578,IC50,"Besides, the IC50 for TCE, imperatorin and isoimperatorin inhibiting ligustrazine metabolism were 5.0 ± 1.02, 1.35 ± 0.46, 4.81 ± 1.14 µg/mL in human liver microsomes, and 13.69 ± 1.11, 1.19 ± 1.09, 1.69 ± 1.17 µg/mL in rat liver microsomes, respectively.",A Metabolism-Based Synergy for Total Coumarin Extract of Radix Angelicae Dahuricae and Ligustrazine on Migraine Treatment in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29693578/),[μg] / [ml],4.81,2204,DB00435,Nitric Oxide
,29693578,IC50,"Besides, the IC50 for TCE, imperatorin and isoimperatorin inhibiting ligustrazine metabolism were 5.0 ± 1.02, 1.35 ± 0.46, 4.81 ± 1.14 µg/mL in human liver microsomes, and 13.69 ± 1.11, 1.19 ± 1.09, 1.69 ± 1.17 µg/mL in rat liver microsomes, respectively.",A Metabolism-Based Synergy for Total Coumarin Extract of Radix Angelicae Dahuricae and Ligustrazine on Migraine Treatment in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29693578/),[μg] / [ml],13.69,2205,DB00435,Nitric Oxide
,29693578,IC50,"Besides, the IC50 for TCE, imperatorin and isoimperatorin inhibiting ligustrazine metabolism were 5.0 ± 1.02, 1.35 ± 0.46, 4.81 ± 1.14 µg/mL in human liver microsomes, and 13.69 ± 1.11, 1.19 ± 1.09, 1.69 ± 1.17 µg/mL in rat liver microsomes, respectively.",A Metabolism-Based Synergy for Total Coumarin Extract of Radix Angelicae Dahuricae and Ligustrazine on Migraine Treatment in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29693578/),[μg] / [ml],1.19,2206,DB00435,Nitric Oxide
,29693578,IC50,"Besides, the IC50 for TCE, imperatorin and isoimperatorin inhibiting ligustrazine metabolism were 5.0 ± 1.02, 1.35 ± 0.46, 4.81 ± 1.14 µg/mL in human liver microsomes, and 13.69 ± 1.11, 1.19 ± 1.09, 1.69 ± 1.17 µg/mL in rat liver microsomes, respectively.",A Metabolism-Based Synergy for Total Coumarin Extract of Radix Angelicae Dahuricae and Ligustrazine on Migraine Treatment in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29693578/),[μg] / [ml],1.69,2207,DB00435,Nitric Oxide
<,29693578,IC50,"Moreover, imperatorin and isoimperatorin were CYP450s inhibitors with IC50 < 10 µM for CYP1A2, 2C9, 2D6, and 3A4.",A Metabolism-Based Synergy for Total Coumarin Extract of Radix Angelicae Dahuricae and Ligustrazine on Migraine Treatment in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29693578/),μM,10,2208,DB00435,Nitric Oxide
,18474366,IC(50),Artepillin C also decreased the number of neutrophils during peritonitis (IC(50): 0.9 (0.5-1.4) mg/kg).,"Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[mg] / [kg],0.9,6319,DB00435,Nitric Oxide
,18474366,ID(50),"Treatment with Artepillin C decreased prostaglandin E(2) by 29+/-3% and 58+/-5% at 1 and 10 mg/kg, respectively, with a mean ID(50) of 8.5 (8.0-8.7) mg/kg).","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[mg] / [kg],8.5,6320,DB00435,Nitric Oxide
,18474366,IC(50),"Similarly, in in vitro models, Artepillin C (3, 10, or 100 microM) decreased nitric oxide production by RAW 264.7 cells with a mean IC(50) of 8.5 (7.8-9.2) microM.","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),μM,8.5,6321,DB00435,Nitric Oxide
,18474366,IC(50),"In HEK 293 cells, Artepillin C reduced NF-kappaB activity with a mean IC(50) of 26 (22-30) mug/ml), suggesting anti-inflammatory activity, particularly during acute inflammation.","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[μg] / [ml],26,6322,DB00435,Nitric Oxide
,18474366,maximal peaks,"Lastly, Artepillin C was absorbed after an oral dose (10 mg/kg) with maximal peaks found at 1 h (22 microg/ml).","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[μg] / [ml],22,6323,DB00435,Nitric Oxide
,7539338,volume of distribution,"The volume of distribution of nitrate was 0.71 +/- 0.04 l/kg and the clearance was 0.32 +/- 0.02 l/h-1/kg-1 (plasma half-life, 1.54 h).",Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7539338/),[l] / [kg],0.71,8770,DB00435,Nitric Oxide
,7539338,clearance,"The volume of distribution of nitrate was 0.71 +/- 0.04 l/kg and the clearance was 0.32 +/- 0.02 l/h-1/kg-1 (plasma half-life, 1.54 h).",Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7539338/),[l] / [h],0.32,8771,DB00435,Nitric Oxide
,7539338,plasma half-life,"The volume of distribution of nitrate was 0.71 +/- 0.04 l/kg and the clearance was 0.32 +/- 0.02 l/h-1/kg-1 (plasma half-life, 1.54 h).",Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7539338/),h,1.54,8772,DB00435,Nitric Oxide
,25160518,trough levels,Tacrolimus was titrated to achieve trough levels of 8-12 ng/ml.,A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[ng] / [ml],8-12,9577,DB00435,Nitric Oxide
,25160518,C0,"Mean Tac C0 was 11.0 ± 2.2 and 11.3 ± 1.8 ng/ml for Tac-ER and Tac-IR, respectively.",A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[ng] / [ml],11.0,9578,DB00435,Nitric Oxide
,25160518,C0,"Mean Tac C0 was 11.0 ± 2.2 and 11.3 ± 1.8 ng/ml for Tac-ER and Tac-IR, respectively.",A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[ng] / [ml],11.3,9579,DB00435,Nitric Oxide
,25160518,Effective 24 h renal plasma flow (ERPF),"The mean Effective 24 h renal plasma flow (ERPF) was significantly higher with Tac-ER compared with Tac-IR (658 ± 127 vs. 610 ± 93 ml/min/1.73 m(2) , P = 0.046).",A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[1.73·min·ml] / [m(2],658,9580,DB00435,Nitric Oxide
,25160518,Effective 24 h renal plasma flow (ERPF),"The mean Effective 24 h renal plasma flow (ERPF) was significantly higher with Tac-ER compared with Tac-IR (658 ± 127 vs. 610 ± 93 ml/min/1.73 m(2) , P = 0.046).",A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[1.73·min·ml] / [m(2],610,9581,DB00435,Nitric Oxide
,26873098,TEAC,TEAC was 11.4 ± 0.2 mmol/L for BTJ and 3.4 ± 0.4 μmol/g for BF.,The plasma bioavailability of nitrate and betanin from Beta vulgaris rubra in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873098/),[mM] / [l],11.4,11503,DB00435,Nitric Oxide
,26873098,TEAC,TEAC was 11.4 ± 0.2 mmol/L for BTJ and 3.4 ± 0.4 μmol/g for BF.,The plasma bioavailability of nitrate and betanin from Beta vulgaris rubra in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873098/),[μM] / [g],3.4,11504,DB00435,Nitric Oxide
,32889741,IC50,"Among them, 12r showed the most potent inhibition with an IC50 value of 5.66 ± 0.47 μM.","Design, synthesis and anti-inflammatory study of novel N-heterocyclic substituted Aloe-emodin derivatives. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889741/),μM,5.66,16394,DB00435,Nitric Oxide
up to,32889741,oral bioavailability,"Importantly, 12r showed oral bioavailability of up to 55.16% and attenuated the inflammatory symptoms in an ulcerative colitis mouse model in vivo.","Design, synthesis and anti-inflammatory study of novel N-heterocyclic substituted Aloe-emodin derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889741/),%,55.16,16395,DB00435,Nitric Oxide
,26526990,TOT-SIL,"Despite a high between-subject variability, repeated administration of Siliphos achieved levels of TOT-SIL of 31,121 to 7,654 ng/mL in the plasma and up to 1,375 ng/g in breast cancer tissue.",A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26526990/),[ng] / [ml],"31,121 to 7,654",16850,DB00435,Nitric Oxide
up,26526990,TOT-SIL,"Despite a high between-subject variability, repeated administration of Siliphos achieved levels of TOT-SIL of 31,121 to 7,654 ng/mL in the plasma and up to 1,375 ng/g in breast cancer tissue.",A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26526990/),[ng] / [g],1,16851,DB00435,Nitric Oxide
,26526990,concentrations,"SIL concentrations ranged from 10,861 to 1,818 ng/mL in plasma and up to 177 ng/g in breast cancer tissue.",A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26526990/),[ng] / [ml],"10,861 to 1,818",16852,DB00435,Nitric Oxide
,28147711,loading efficiency,The loading efficiency of SF was 19.33 ± 1.28%.,Pharmacokinetics and in vitro and in vivo delivery of sulforaphane by PCL-PEG-PCL copolymeric-based micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28147711/),%,19.33,16968,DB00435,Nitric Oxide
,28147711,mean residence time,"Also, in comparison with the free-SF solution, encapsulation of the SF in micelles increased the mean residence time from 0.5 to 4 h and the area under the concentration-time curve up to 50 folds.",Pharmacokinetics and in vitro and in vivo delivery of sulforaphane by PCL-PEG-PCL copolymeric-based micelles. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28147711/),h,0.5,16969,DB00435,Nitric Oxide
,28147711,mean residence time,"Also, in comparison with the free-SF solution, encapsulation of the SF in micelles increased the mean residence time from 0.5 to 4 h and the area under the concentration-time curve up to 50 folds.",Pharmacokinetics and in vitro and in vivo delivery of sulforaphane by PCL-PEG-PCL copolymeric-based micelles. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28147711/),h,4,16970,DB00435,Nitric Oxide
,1578380,half-lives,"Using this pharmacodynamic model, the in vivo half-lives of nitric oxide and cGMP were estimated to be 1.6 and 2.0 min, respectively.",Pharmacokinetic/pharmacodynamic relationship of the duration of vasodilating action of organic mononitrates in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1578380/),min,1.6,17451,DB00435,Nitric Oxide
,1578380,half-lives,"Using this pharmacodynamic model, the in vivo half-lives of nitric oxide and cGMP were estimated to be 1.6 and 2.0 min, respectively.",Pharmacokinetic/pharmacodynamic relationship of the duration of vasodilating action of organic mononitrates in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1578380/),min,2.0,17452,DB00435,Nitric Oxide
,10899290,IC(50),"The IC(50) values for ARL 17477 on human recombinant human nNOS and eNOS were 1 and 17 microM, respectively.","ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10899290/),μM,1,24401,DB00435,Nitric Oxide
,10899290,IC(50),"The IC(50) values for ARL 17477 on human recombinant human nNOS and eNOS were 1 and 17 microM, respectively.","ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10899290/),μM,17,24402,DB00435,Nitric Oxide
,9833603,Oral bioavailability,Oral bioavailability of L-arginine was 68+/-9 (51-87)%.,L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833603/),%,68,25210,DB00435,Nitric Oxide
,9833603,Clearance,"Clearance was 544+/-24 (440-620), 894+/-164 (470-1190), and 1018+/-230 (710-2130) ml min(-1), and elimination half-life was calculated as 41.6+/-2.3 (34-55), 59.6+/-9.1 (24-98), and 79.5+/-9.3 (50-121) min, respectively, for 30 g i.v., 6 g i.v., and 6 g p.o. of L-arginine.",L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833603/),[ml] / [min],544,25211,DB00435,Nitric Oxide
,9833603,Clearance,"Clearance was 544+/-24 (440-620), 894+/-164 (470-1190), and 1018+/-230 (710-2130) ml min(-1), and elimination half-life was calculated as 41.6+/-2.3 (34-55), 59.6+/-9.1 (24-98), and 79.5+/-9.3 (50-121) min, respectively, for 30 g i.v., 6 g i.v., and 6 g p.o. of L-arginine.",L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833603/),[ml] / [min],894,25212,DB00435,Nitric Oxide
,9833603,Clearance,"Clearance was 544+/-24 (440-620), 894+/-164 (470-1190), and 1018+/-230 (710-2130) ml min(-1), and elimination half-life was calculated as 41.6+/-2.3 (34-55), 59.6+/-9.1 (24-98), and 79.5+/-9.3 (50-121) min, respectively, for 30 g i.v., 6 g i.v., and 6 g p.o. of L-arginine.",L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833603/),[ml] / [min],1018,25213,DB00435,Nitric Oxide
,9833603,elimination half-life,"Clearance was 544+/-24 (440-620), 894+/-164 (470-1190), and 1018+/-230 (710-2130) ml min(-1), and elimination half-life was calculated as 41.6+/-2.3 (34-55), 59.6+/-9.1 (24-98), and 79.5+/-9.3 (50-121) min, respectively, for 30 g i.v., 6 g i.v., and 6 g p.o. of L-arginine.",L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833603/),min,41.6,25214,DB00435,Nitric Oxide
,9833603,elimination half-life,"Clearance was 544+/-24 (440-620), 894+/-164 (470-1190), and 1018+/-230 (710-2130) ml min(-1), and elimination half-life was calculated as 41.6+/-2.3 (34-55), 59.6+/-9.1 (24-98), and 79.5+/-9.3 (50-121) min, respectively, for 30 g i.v., 6 g i.v., and 6 g p.o. of L-arginine.",L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833603/),min,59.6,25215,DB00435,Nitric Oxide
,9833603,elimination half-life,"Clearance was 544+/-24 (440-620), 894+/-164 (470-1190), and 1018+/-230 (710-2130) ml min(-1), and elimination half-life was calculated as 41.6+/-2.3 (34-55), 59.6+/-9.1 (24-98), and 79.5+/-9.3 (50-121) min, respectively, for 30 g i.v., 6 g i.v., and 6 g p.o. of L-arginine.",L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833603/),min,79.5,25216,DB00435,Nitric Oxide
,9833603,half-life,"The onset and the duration of the vasodilator effect of L-arginine and its effects on endogenous NO production closely corresponded to the plasma concentration half-life of L-arginine, as indicated by an equilibration half-life of 6+/-2 (3.7-8.4) min between plasma concentration and effect in pharmacokinetic-pharmacodynamic analysis, and the lack of hysteresis in the plasma concentration-versus-effect plot.",L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833603/),min,6,25217,DB00435,Nitric Oxide
,7521951,Half-live,Half-live of N-nitroso-L-arginine was 4 s in rat brain cortex and the washout curve of NO after over brain insufflation gave an half-life of 10.5 min; their diffusion coefficients in brain were 3.810(-5) for NO and 3.910(-6) cm2.s-1 for N-nitroso-L-arginine.,Diffusion coefficients and half-lives of nitric oxide and N-nitroso-L-arginine in rat cortex. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521951/),s,4,29109,DB00435,Nitric Oxide
,7521951,half-life,Half-live of N-nitroso-L-arginine was 4 s in rat brain cortex and the washout curve of NO after over brain insufflation gave an half-life of 10.5 min; their diffusion coefficients in brain were 3.810(-5) for NO and 3.910(-6) cm2.s-1 for N-nitroso-L-arginine.,Diffusion coefficients and half-lives of nitric oxide and N-nitroso-L-arginine in rat cortex. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521951/),min,10.5,29110,DB00435,Nitric Oxide
,7521951,diffusion coefficients,Half-live of N-nitroso-L-arginine was 4 s in rat brain cortex and the washout curve of NO after over brain insufflation gave an half-life of 10.5 min; their diffusion coefficients in brain were 3.810(-5) for NO and 3.910(-6) cm2.s-1 for N-nitroso-L-arginine.,Diffusion coefficients and half-lives of nitric oxide and N-nitroso-L-arginine in rat cortex. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521951/),(,3.810,29111,DB00435,Nitric Oxide
,7521951,diffusion coefficients,Half-live of N-nitroso-L-arginine was 4 s in rat brain cortex and the washout curve of NO after over brain insufflation gave an half-life of 10.5 min; their diffusion coefficients in brain were 3.810(-5) for NO and 3.910(-6) cm2.s-1 for N-nitroso-L-arginine.,Diffusion coefficients and half-lives of nitric oxide and N-nitroso-L-arginine in rat cortex. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521951/),[cm2] / [s],3.910,29112,DB00435,Nitric Oxide
,8744668,Arterial plasma concentrations,"Arterial plasma concentrations of bupivacaine 5 minutes after the start of bupivacaine infusion were significantly higher in the L-NAME than in the saline group (22.3 +/- 2.9 vs 12.8 +/- 1.5 micrograms/mL, P < .05).",Nitric oxide synthesis inhibition enhances bupivacaine cardiotoxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8744668/),[μg] / [ml],22.3,30592,DB00435,Nitric Oxide
,8744668,Arterial plasma concentrations,"Arterial plasma concentrations of bupivacaine 5 minutes after the start of bupivacaine infusion were significantly higher in the L-NAME than in the saline group (22.3 +/- 2.9 vs 12.8 +/- 1.5 micrograms/mL, P < .05).",Nitric oxide synthesis inhibition enhances bupivacaine cardiotoxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8744668/),[μg] / [ml],12.8,30593,DB00435,Nitric Oxide
,12584267,Maximum end,"Maximum endothelium-dependent relaxation was enhanced in ET-1 transgenic mice (93+/-3% vs 84+/-4% for wild-type littermates; P<0.05) and was inhibited by preincubation with L-NAME in both ET-transgenic mice and wild-type littermates (11+/-5% vs 9+/-4% maximum relaxation, respectively).",Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584267/),%,93,30602,DB00435,Nitric Oxide
,12584267,Maximum end,"Maximum endothelium-dependent relaxation was enhanced in ET-1 transgenic mice (93+/-3% vs 84+/-4% for wild-type littermates; P<0.05) and was inhibited by preincubation with L-NAME in both ET-transgenic mice and wild-type littermates (11+/-5% vs 9+/-4% maximum relaxation, respectively).",Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584267/),%,84,30603,DB00435,Nitric Oxide
,12584267,maximum relaxation,"Maximum endothelium-dependent relaxation was enhanced in ET-1 transgenic mice (93+/-3% vs 84+/-4% for wild-type littermates; P<0.05) and was inhibited by preincubation with L-NAME in both ET-transgenic mice and wild-type littermates (11+/-5% vs 9+/-4% maximum relaxation, respectively).",Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584267/),%,9,30604,DB00435,Nitric Oxide
,32787767,Δ1,"Compared to patients with T2DM, serum NOx concentration (Δ1= 16.7 vs. 4.4 μmol/L, P=0.057) of healthy subjects sharply increased within 1 hour after NO3 loading.",Different Pharmacokinetic Responses to an Acute Dose of Inorganic Nitrate in Patients with Type 2 Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787767/),[μM] / [l],16.7,31614,DB00435,Nitric Oxide
,32787767,Δ1,"Compared to patients with T2DM, serum NOx concentration (Δ1= 16.7 vs. 4.4 μmol/L, P=0.057) of healthy subjects sharply increased within 1 hour after NO3 loading.",Different Pharmacokinetic Responses to an Acute Dose of Inorganic Nitrate in Patients with Type 2 Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787767/),[μM] / [l],4.4,31615,DB00435,Nitric Oxide
higher,24272172,entrapment efficiency,The sanguinarine solid lipid nanoparticles (SG-SLNs) were prepared by film-ultrasonic dispersion method and the entrapment efficiency of SG was higher at 75.6 %.,Pharmacokinetic and anti-inflammatory effects of sanguinarine solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24272172/),%,75.6,33520,DB00435,Nitric Oxide
,14570719,total number of,"On naproxen, the mean total number of gastroduodenal erosions was 11.5 (and one subject developed an acute ulcer) versus 4.1 on AZD3582 (p<0.0001).","Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570719/),,11.5,37234,DB00435,Nitric Oxide
,14570719,total number of,"On naproxen, the mean total number of gastroduodenal erosions was 11.5 (and one subject developed an acute ulcer) versus 4.1 on AZD3582 (p<0.0001).","Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570719/),,4.1,37235,DB00435,Nitric Oxide
,14570719,steady state bioavailability,The steady state bioavailability of naproxen metabolised from AZD3582 was 95% (95% confidence interval 87-101%) of that after naproxen administration.,"Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570719/),%,95,37236,DB00435,Nitric Oxide
,7796509,plasma half-life,The plasma half-life was calculated as 3.8 hours.,Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7796509/),h,3.8,38947,DB00435,Nitric Oxide
,7796509,volume of distribution,"The volume of distribution was calculated as 0.215 L/kg, or equivalent to the extracellular volume.",Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7796509/),[l] / [kg],0.215,38948,DB00435,Nitric Oxide
,15933157,half-life,Agmatine persisted at near maximum concentrations in all levels of the spinal cord for several hours with a half-life of approximately 12 h.,Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933157/),h,12,40837,DB00435,Nitric Oxide
less,15933157,serum half-life,"However, the serum half-life was less than 10 min after intrathecal injection of agmatine, consistent with previous preliminary pharmacokinetic reports of systemically administered agmatine.",Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933157/),min,10,40838,DB00435,Nitric Oxide
,22840695,IC(50),"We recently reported a series of 1,6-disubstituted indoline-based thiophene amidine compounds (5) as selective neuronal nitric oxide synthase (nNOS) inhibitors to mitigate the cardiovascular liabilities associated with hERG K(+) channel inhibition (IC(50) = 4.7 μM) with previously reported tetrahydroquinoline-based selective nNOS inhibitors (4).","Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22840695/),μM,4.7,44653,DB00435,Nitric Oxide
,22840695,oral bioavailability (F(po),"The in vivo activity in two different pain (spinal nerve ligation and migraine pain) models, the excellent physicochemical and pharmacokinetic properties, oral bioavailability (F(po) = 91%), and the in vitro safety profile disclosed in this report make 43 an ideal candidate for further evaluation in clinical applications related to migraine pain.","Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22840695/),%,91,44654,DB00435,Nitric Oxide
,31578035,AUC0-48 h,"Data from group A was used to determine the dose for group B, aiming at an AUC0-48 h of 4800 ng*h/mL.",Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578035/),[h·ng] / [ml],4800,48627,DB00435,Nitric Oxide
,31578035,AUC0-48 h,"Exposure in group A was higher than targeted (median AUC0-48 h 9522 ng*h/mL); subsequently, group B (n = 6) received eight doses of 0.08 mg/kg q6h (median AUC0-48 h 4465 ng*h/mL).",Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578035/),[h·ng] / [ml],9522,48628,DB00435,Nitric Oxide
,31578035,AUC0-48 h,"Exposure in group A was higher than targeted (median AUC0-48 h 9522 ng*h/mL); subsequently, group B (n = 6) received eight doses of 0.08 mg/kg q6h (median AUC0-48 h 4465 ng*h/mL).",Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578035/),[h·ng] / [ml],4465,48629,DB00435,Nitric Oxide
,29086344,bioavailability,"It is rapidly absorbed, displays almost complete bioavailability (94.3%), and can be taken with or without food and as crushed or whole tablets.",Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29086344/),%,94.3,48636,DB00435,Nitric Oxide
,29086344,half-life,The half-life of riociguat is approximately 12 h in patients and approximately 7 h in healthy individuals.,Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29086344/),h,12,48637,DB00435,Nitric Oxide
,29086344,half-life,The half-life of riociguat is approximately 12 h in patients and approximately 7 h in healthy individuals.,Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29086344/),h,7,48638,DB00435,Nitric Oxide
,19070554,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of S(15)NALB from rat plasma was determined to be 4.1 min (t(1/2)alpha) and 9.4 min (t(1/2)beta).,Application of a stable-isotope dilution technique to study the pharmacokinetics of human 15N-labelled S-nitrosoalbumin in the rat: possible mechanistic and biological implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19070554/),min,4.1,51639,DB00435,Nitric Oxide
,19070554,t(1/2)alpha,The elimination half-life (t(1/2)) of S(15)NALB from rat plasma was determined to be 4.1 min (t(1/2)alpha) and 9.4 min (t(1/2)beta).,Application of a stable-isotope dilution technique to study the pharmacokinetics of human 15N-labelled S-nitrosoalbumin in the rat: possible mechanistic and biological implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19070554/),min,4.1,51640,DB00435,Nitric Oxide
,19070554,t(1/2)beta,The elimination half-life (t(1/2)) of S(15)NALB from rat plasma was determined to be 4.1 min (t(1/2)alpha) and 9.4 min (t(1/2)beta).,Application of a stable-isotope dilution technique to study the pharmacokinetics of human 15N-labelled S-nitrosoalbumin in the rat: possible mechanistic and biological implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19070554/),min,9.4,51641,DB00435,Nitric Oxide
,17662090,ratio,"The highest dose of citrulline (3 g bid) increased the C(min) of plasma L-arginine and improved the L-arginine/ADMA ratio from 186 +/- 8 (baseline) to 278 +/- 14 [P < 0.01, 95% confidence interval (CI) 66, 121].",Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17662090/),,186,55714,DB00435,Nitric Oxide
,17662090,ratio,"The highest dose of citrulline (3 g bid) increased the C(min) of plasma L-arginine and improved the L-arginine/ADMA ratio from 186 +/- 8 (baseline) to 278 +/- 14 [P < 0.01, 95% confidence interval (CI) 66, 121].",Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17662090/),,278,55715,DB00435,Nitric Oxide
,8940720,half-life,Using positron emission tomography (PET) and nitric oxide radiolabeled with nitrogen-13 (half-life 9.97 min) we probed the distribution and kinetics of inhaled nitric oxide in anesthetized dogs.,Inhaled [13N]nitric oxide: a positron emission tomography (PET) study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8940720/),min,9.97,60649,DB00435,Nitric Oxide
,19122316,lag time,"The pellets achieved a lag time of 4.1 h in vivo, which had a good consistency with the in vitro results, and the relative bioavailability was nearly 100% comparing to the normal tablets.",Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122316/),h,4.1,63173,DB00435,Nitric Oxide
,19122316,relative bioavailability,"The pellets achieved a lag time of 4.1 h in vivo, which had a good consistency with the in vitro results, and the relative bioavailability was nearly 100% comparing to the normal tablets.",Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122316/),%,100,63174,DB00435,Nitric Oxide
,12201491,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) in mouse, rabbit, rat and human was 30, 99, 330, and 99 mg/kg respectively.","5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12201491/),[mg] / [kg],30,63682,DB00435,Nitric Oxide
,12201491,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) in mouse, rabbit, rat and human was 30, 99, 330, and 99 mg/kg respectively.","5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12201491/),[mg] / [kg],99,63683,DB00435,Nitric Oxide
,12201491,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) in mouse, rabbit, rat and human was 30, 99, 330, and 99 mg/kg respectively.","5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12201491/),[mg] / [kg],330,63684,DB00435,Nitric Oxide
,26902772,mean residence time,"In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h).",Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902772/),h,7.55,65732,DB00435,Nitric Oxide
,26902772,mean residence time,"In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h).",Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902772/),h,1.46,65733,DB00435,Nitric Oxide
,16354398,plasma protein binding degree,"AZD3582 has a predicted plasma protein binding degree of approximately 0.1%, a half-life (t1/2) of 3 to 10 h and does not accumulate after repeated once- and twice-daily dosing.",Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354398/),%,0.1,68560,DB00435,Nitric Oxide
,16354398,half-life (t1/2),"AZD3582 has a predicted plasma protein binding degree of approximately 0.1%, a half-life (t1/2) of 3 to 10 h and does not accumulate after repeated once- and twice-daily dosing.",Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354398/),h,3 to 10,68561,DB00435,Nitric Oxide
,16354398,F,The uptake of naproxen is slightly slower and lower (> or = 94% relative GI uptake and 80-85% relative F) after AZD3582 administration compared with naproxen dosing.,Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354398/),%,94,68562,DB00435,Nitric Oxide
,16354398,F,The uptake of naproxen is slightly slower and lower (> or = 94% relative GI uptake and 80-85% relative F) after AZD3582 administration compared with naproxen dosing.,Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354398/),%,80-85,68563,DB00435,Nitric Oxide
,11758770,apparent IC50,The decrease in NOS activity by 7-NI was concentration-dependent with an apparent IC50 of approximately 17 microg/ml.,"Pharmacokinetics and pharmacodynamics of 7-nitroindazole, a selective nitric oxide synthase inhibitor, in the rat hippocampus. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758770/),[μg] / [ml],17,68615,DB00435,Nitric Oxide
,25040039,Cmax,"Pharmacokinetic data showed AQX-1125 was rapidly absorbed with geometric mean Cmax and AUC0-24 h values of 1417 ng/mL and 16 727 h ng/mL, respectively.",The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25040039/),[ng] / [ml],1417,69032,DB00435,Nitric Oxide
,25040039,AUC0-24 h,"Pharmacokinetic data showed AQX-1125 was rapidly absorbed with geometric mean Cmax and AUC0-24 h values of 1417 ng/mL and 16 727 h ng/mL, respectively.",The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25040039/),[h·ng] / [ml],16 727,69033,DB00435,Nitric Oxide
,12885396,binding,"In vitro binding of INUdR to bovine serum albumin (BSA) was estimated using an ultrafiltration method to be 65 to 77%, depending on the INUdR concentration.",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),%,65,73271,DB00435,Nitric Oxide
,12885396,elimination half-life (T(1/2),"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),h,0.27,73272,DB00435,Nitric Oxide
,12885396,steady-state volume of distribution (V(ss),"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),[l] / [kg],0.89,73273,DB00435,Nitric Oxide
,12885396,oral bioavailability (F,"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),,0.95,73274,DB00435,Nitric Oxide
,9918901,normalized area-under-the-curve for 8 h (AUC0-8),"The L-arginine exposure, expressed as a normalized area-under-the-curve for 8 h (AUC0-8) after oral or intravenous doses during the first visit, was 894.4+/-118.7 and 1837.",Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918901/),,894.4,74928,DB00435,Nitric Oxide
,9918901,normalized area-under-the-curve for 8 h (AUC0-8),"The L-arginine exposure, expressed as a normalized area-under-the-curve for 8 h (AUC0-8) after oral or intravenous doses during the first visit, was 894.4+/-118.7 and 1837.",Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918901/),,1837,74929,DB00435,Nitric Oxide
,9105229,half-life,"Plasma clearance of rHb1.1 decreased and half-life increased as a function of increasing plasma concentration (e.g., the half-life was 2.8 h at a plasma concentration of 0.5 mg/ml and 12 h at 5 mg/ml).",Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105229/),h,2.8,78864,DB00435,Nitric Oxide
,9105229,half-life,"Plasma clearance of rHb1.1 decreased and half-life increased as a function of increasing plasma concentration (e.g., the half-life was 2.8 h at a plasma concentration of 0.5 mg/ml and 12 h at 5 mg/ml).",Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105229/),h,12,78865,DB00435,Nitric Oxide
,34019417,IC50,"Compound 18, with the most potent activity (IC50 = 74 nM), high BBB permeability (Pe = 19.1 × 10-6 cm/s), and high selectivity over other NOS isoforms, was selected as the lead compound.",Optimization of N-Phenylpropenoyl-l-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson's Disease. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019417/),nM,74,78978,DB00435,Nitric Oxide
,34019417,Pe,"Compound 18, with the most potent activity (IC50 = 74 nM), high BBB permeability (Pe = 19.1 × 10-6 cm/s), and high selectivity over other NOS isoforms, was selected as the lead compound.",Optimization of N-Phenylpropenoyl-l-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson's Disease. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019417/),[cm] / [s],19.1 × 10-6,78979,DB00435,Nitric Oxide
,7858710,half-life,"L-NAME was unstable in sheep plasma at 37 degrees C, and was converted to L-NOLA with a half-life of 250 min.",Determination of NG-nitro-L-arginine and NG-nitro-L-arginine methyl ester in plasma by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7858710/),min,250,79118,DB00435,Nitric Oxide
,30422390,half-life,"Pharmacokinetics were dose proportional, with an effective half-life of 24-37 hours, supporting once-daily dosing.","A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30422390/),h,24-37,83212,DB00435,Nitric Oxide
,14561847,half-life,"Methylecgonidine clears quickly from blood with a half-life of 18 to 21 min, whereas ecgonidine has a longer half-life of 94 to 137 min.","Pharmacokinetics and pharmacodynamics of methylecgonidine, a crack cocaine pyrolyzate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561847/),min,18 to 21,88463,DB00435,Nitric Oxide
,14561847,half-life,"Methylecgonidine clears quickly from blood with a half-life of 18 to 21 min, whereas ecgonidine has a longer half-life of 94 to 137 min.","Pharmacokinetics and pharmacodynamics of methylecgonidine, a crack cocaine pyrolyzate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561847/),min,94 to 137,88464,DB00435,Nitric Oxide
,17723076,PC(20),"However, S-albuterol reduced the provocative concentration of methacholine to induce a 20% decrease in FEV(1) (PC(20) 0.52 +/- 2.06 vs 0.39 +/- 1.58 mg/ml, placebo vs S-albuterol, p=0.044) but did not affect FeNO.",Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723076/),[mg] / [ml],0.52,90637,DB00435,Nitric Oxide
,17723076,PC(20),"However, S-albuterol reduced the provocative concentration of methacholine to induce a 20% decrease in FEV(1) (PC(20) 0.52 +/- 2.06 vs 0.39 +/- 1.58 mg/ml, placebo vs S-albuterol, p=0.044) but did not affect FeNO.",Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723076/),[mg] / [ml],0.39,90638,DB00435,Nitric Oxide
,8937859,half-lives,"After intravenous administration of a bolus dose of 20 mg/kg in rats, plasma concentrations of both L- and D-NNA declined biexponentially, with average half-lives of 12 min and 20 hr for L-NNA, and 15 min and 15 hr for the D-enantiomer, respectively.",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),min,12,92548,DB00435,Nitric Oxide
,8937859,half-lives,"After intravenous administration of a bolus dose of 20 mg/kg in rats, plasma concentrations of both L- and D-NNA declined biexponentially, with average half-lives of 12 min and 20 hr for L-NNA, and 15 min and 15 hr for the D-enantiomer, respectively.",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),h,20,92549,DB00435,Nitric Oxide
,8937859,half-lives,"After intravenous administration of a bolus dose of 20 mg/kg in rats, plasma concentrations of both L- and D-NNA declined biexponentially, with average half-lives of 12 min and 20 hr for L-NNA, and 15 min and 15 hr for the D-enantiomer, respectively.",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),min,15,92550,DB00435,Nitric Oxide
,8937859,half-lives,"After intravenous administration of a bolus dose of 20 mg/kg in rats, plasma concentrations of both L- and D-NNA declined biexponentially, with average half-lives of 12 min and 20 hr for L-NNA, and 15 min and 15 hr for the D-enantiomer, respectively.",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),h,15,92551,DB00435,Nitric Oxide
,8937859,systemic clearance,"In contrast to L-NNA, the D-isomer had a higher systemic clearance (170 +/- 20 vs. 70.9 +/- 8.2 ml/hr/kg; p = 0.0004) and shorter mean residence time (17.3 +/- 3.7 vs. 31.7 +/- 3.7 hr; p = 0.0039).",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),[ml] / [h·kg],170,92552,DB00435,Nitric Oxide
,8937859,systemic clearance,"In contrast to L-NNA, the D-isomer had a higher systemic clearance (170 +/- 20 vs. 70.9 +/- 8.2 ml/hr/kg; p = 0.0004) and shorter mean residence time (17.3 +/- 3.7 vs. 31.7 +/- 3.7 hr; p = 0.0039).",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),[ml] / [h·kg],70.9,92553,DB00435,Nitric Oxide
,8937859,mean residence time,"In contrast to L-NNA, the D-isomer had a higher systemic clearance (170 +/- 20 vs. 70.9 +/- 8.2 ml/hr/kg; p = 0.0004) and shorter mean residence time (17.3 +/- 3.7 vs. 31.7 +/- 3.7 hr; p = 0.0039).",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),h,17.3,92554,DB00435,Nitric Oxide
,8937859,mean residence time,"In contrast to L-NNA, the D-isomer had a higher systemic clearance (170 +/- 20 vs. 70.9 +/- 8.2 ml/hr/kg; p = 0.0004) and shorter mean residence time (17.3 +/- 3.7 vs. 31.7 +/- 3.7 hr; p = 0.0039).",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),h,31.7,92555,DB00435,Nitric Oxide
,8937859,tissue-to-plasma distribution coefficient (Kp),The tissue-to-plasma distribution coefficient (Kp) for L-NNA was variable among various tissues and ranged from 0.67 for testes to 3.17 for liver.,Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),,0.67,92556,DB00435,Nitric Oxide
,8937859,tissue-to-plasma distribution coefficient (Kp),The tissue-to-plasma distribution coefficient (Kp) for L-NNA was variable among various tissues and ranged from 0.67 for testes to 3.17 for liver.,Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),,3.17,92557,DB00435,Nitric Oxide
higher,8937859,Kp,"Both kidneys and skeletal muscle had Kp values higher than 2, whereas distribution to the cerebrospinal fluid was minimal (Kp = 0.09).",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),,2,92558,DB00435,Nitric Oxide
,8937859,Kp,"Both kidneys and skeletal muscle had Kp values higher than 2, whereas distribution to the cerebrospinal fluid was minimal (Kp = 0.09).",Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937859/),,0.09,92559,DB00435,Nitric Oxide
,23773000,t1/2,"2. In rats, ZJM-289 was eliminated rapidly (t1/2 = 19.2 ± 3.85 min), along with the fast formation of NBP (formation rate constant ka = 0.29 ± 0.092 min(-1) for intravenous group, and ka = 0.16 ± 0.064 min(-1) for intragastric group), accounting for about 47.4 ± 4.0% of ZJM-289.","Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773000/),min,19.2,93609,DB00435,Nitric Oxide
,23773000,formation rate constant ka,"2. In rats, ZJM-289 was eliminated rapidly (t1/2 = 19.2 ± 3.85 min), along with the fast formation of NBP (formation rate constant ka = 0.29 ± 0.092 min(-1) for intravenous group, and ka = 0.16 ± 0.064 min(-1) for intragastric group), accounting for about 47.4 ± 4.0% of ZJM-289.","Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773000/),1/[min],0.29,93610,DB00435,Nitric Oxide
,23773000,ka,"2. In rats, ZJM-289 was eliminated rapidly (t1/2 = 19.2 ± 3.85 min), along with the fast formation of NBP (formation rate constant ka = 0.29 ± 0.092 min(-1) for intravenous group, and ka = 0.16 ± 0.064 min(-1) for intragastric group), accounting for about 47.4 ± 4.0% of ZJM-289.","Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773000/),1/[min],0.16,93611,DB00435,Nitric Oxide
,23773000,t1/2,"Both ZJM-289 (t1/2 = 239 ± 70.4 min) and NBP (t1/2 = 249 ± 39.0 min) were depleted slowly in Beagle dogs, with NBP formation rate constant at 0.12 ± 0.052 min(-1) (ka = 0.15 ± 0.040 min(-1) for intragastric group).","Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773000/),min,239,93612,DB00435,Nitric Oxide
,23773000,t1/2,"Both ZJM-289 (t1/2 = 239 ± 70.4 min) and NBP (t1/2 = 249 ± 39.0 min) were depleted slowly in Beagle dogs, with NBP formation rate constant at 0.12 ± 0.052 min(-1) (ka = 0.15 ± 0.040 min(-1) for intragastric group).","Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773000/),min,249,93613,DB00435,Nitric Oxide
,23773000,formation rate constant,"Both ZJM-289 (t1/2 = 239 ± 70.4 min) and NBP (t1/2 = 249 ± 39.0 min) were depleted slowly in Beagle dogs, with NBP formation rate constant at 0.12 ± 0.052 min(-1) (ka = 0.15 ± 0.040 min(-1) for intragastric group).","Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773000/),1/[min],0.12,93614,DB00435,Nitric Oxide
,23773000,ka,"Both ZJM-289 (t1/2 = 239 ± 70.4 min) and NBP (t1/2 = 249 ± 39.0 min) were depleted slowly in Beagle dogs, with NBP formation rate constant at 0.12 ± 0.052 min(-1) (ka = 0.15 ± 0.040 min(-1) for intragastric group).","Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773000/),1/[min],0.15,93615,DB00435,Nitric Oxide
,23773000,t1/2,"3. In rat plasma, ZJM-289 was degraded rapidly (t1/2 = 24.3 ± 0.93 min) at 37 °C, but remained stable with almost no cleavage in dog and human plasma.","Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773000/),min,24.3,93616,DB00435,Nitric Oxide
,26504409,peak serum concentration (C Max),"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),[μg] / [ml],30.06,95769,DB00435,Nitric Oxide
,26504409,time it takes to reach peak serum concentration (t Max),"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),h,1.13,95770,DB00435,Nitric Oxide
,26504409,C Max,"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),[μg] / [ml],2.99,95771,DB00435,Nitric Oxide
,26504409,t Max,"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),h,2.44,95772,DB00435,Nitric Oxide
,26504409,t 1/2,"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),h,34.56,95773,DB00435,Nitric Oxide
,31960360,AUC0-4h,"Neonates received six infusions of 2-iminobiotin 0.16 mg/kg started within 6 h after birth, with 4-h intervals, targeting an AUC0-4h of 365 ng*h/mL.","A Phase IIa Clinical Trial of 2-Iminobiotin for the Treatment of Birth Asphyxia in DR Congo, a Low-Income Country. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31960360/),[h·ng] / [ml],365,97766,DB00435,Nitric Oxide
,31960360,AUC0-4h,Median AUC0-4h was 664 ng*h/mL (range 414-917).,"A Phase IIa Clinical Trial of 2-Iminobiotin for the Treatment of Birth Asphyxia in DR Congo, a Low-Income Country. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31960360/),[h·ng] / [ml],664,97767,DB00435,Nitric Oxide
,8772744,systemic vascular resistance,"During normoxia, L-NMMA increased systemic vascular resistance from 1,108 +/- 74 to 1,705 +/- 87 dynes-s-cm-5 and increased pulmonary vascular resistance from 60 +/- 5 to 115 +/- 9 dynes-s-cm-5 (p < or = 0.01 for each).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],"1,108",97972,DB00435,Nitric Oxide
,8772744,systemic vascular resistance,"During normoxia, L-NMMA increased systemic vascular resistance from 1,108 +/- 74 to 1,705 +/- 87 dynes-s-cm-5 and increased pulmonary vascular resistance from 60 +/- 5 to 115 +/- 9 dynes-s-cm-5 (p < or = 0.01 for each).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],"1,705",97973,DB00435,Nitric Oxide
,8772744,pulmonary vascular resistance,"During normoxia, L-NMMA increased systemic vascular resistance from 1,108 +/- 74 to 1,705 +/- 87 dynes-s-cm-5 and increased pulmonary vascular resistance from 60 +/- 5 to 115 +/- 9 dynes-s-cm-5 (p < or = 0.01 for each).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],60,97974,DB00435,Nitric Oxide
,8772744,pulmonary vascular resistance,"During normoxia, L-NMMA increased systemic vascular resistance from 1,108 +/- 74 to 1,705 +/- 87 dynes-s-cm-5 and increased pulmonary vascular resistance from 60 +/- 5 to 115 +/- 9 dynes-s-cm-5 (p < or = 0.01 for each).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],115,97975,DB00435,Nitric Oxide
,8772744,systemic vascular resistance,"Acute hypoxia alone decreased systemic vascular resistance from 1,209 +/- 78 to 992 +/- 58 dynes-s-cm-5 (p < or = 0.05) and increased pulmonary vascular resistance from 92 +/- 11 to 136 +/- 4 dynes-s-cm-5 (p < or = 0.01).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],"1,209",97976,DB00435,Nitric Oxide
,8772744,systemic vascular resistance,"Acute hypoxia alone decreased systemic vascular resistance from 1,209 +/- 78 to 992 +/- 58 dynes-s-cm-5 (p < or = 0.05) and increased pulmonary vascular resistance from 92 +/- 11 to 136 +/- 4 dynes-s-cm-5 (p < or = 0.01).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],992,97977,DB00435,Nitric Oxide
,8772744,pulmonary vascular resistance,"Acute hypoxia alone decreased systemic vascular resistance from 1,209 +/- 78 to 992 +/- 58 dynes-s-cm-5 (p < or = 0.05) and increased pulmonary vascular resistance from 92 +/- 11 to 136 +/- 4 dynes-s-cm-5 (p < or = 0.01).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],92,97978,DB00435,Nitric Oxide
,8772744,pulmonary vascular resistance,"Acute hypoxia alone decreased systemic vascular resistance from 1,209 +/- 78 to 992 +/- 58 dynes-s-cm-5 (p < or = 0.05) and increased pulmonary vascular resistance from 92 +/- 11 to 136 +/- 4 dynes-s-cm-5 (p < or = 0.01).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],136,97979,DB00435,Nitric Oxide
,8772744,systemic vascular resistance,"While hypoxic conditions were maintained, infusion of L-NMMA increased systemic vascular resistance (to 1,496 +/- 97 dynes-s-cm-5, p < or = 0.01) and increased pulmonary vascular resistance further (to 217 +/- 25 dynes-s-cm-5, p < or = 0.01).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],"1,496",97980,DB00435,Nitric Oxide
,8772744,pulmonary vascular resistance,"While hypoxic conditions were maintained, infusion of L-NMMA increased systemic vascular resistance (to 1,496 +/- 97 dynes-s-cm-5, p < or = 0.01) and increased pulmonary vascular resistance further (to 217 +/- 25 dynes-s-cm-5, p < or = 0.01).",Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772744/),1/[(dynes-s-cm)^5],217,97981,DB00435,Nitric Oxide
,17324140,area under the time-course curve (AUC(0-24h)),"3. In the NCX899 group, the area under the time-course curve (AUC(0-24h)) was 29.18 +/- 4.72, 229.37 +/- 51.32 and 5159.23 +/- 514.88 microg.h/L for the analytes nitro-enalapril, enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],29.18,102296,DB00435,Nitric Oxide
,17324140,area under the time-course curve (AUC(0-24h)),"3. In the NCX899 group, the area under the time-course curve (AUC(0-24h)) was 29.18 +/- 4.72, 229.37 +/- 51.32 and 5159.23 +/- 514.88 microg.h/L for the analytes nitro-enalapril, enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],229.37,102297,DB00435,Nitric Oxide
,17324140,area under the time-course curve (AUC(0-24h)),"3. In the NCX899 group, the area under the time-course curve (AUC(0-24h)) was 29.18 +/- 4.72, 229.37 +/- 51.32 and 5159.23 +/- 514.88 microg.h/L for the analytes nitro-enalapril, enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],5159.23,102298,DB00435,Nitric Oxide
,17324140,AUC(0-24h),"In the enalapril group, the AUC(0-24h) was 704.53 +/- 158.86 and 4149.27 +/- 847.30 microg.h/L for the analytes enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],704.53,102299,DB00435,Nitric Oxide
,17324140,AUC(0-24h),"In the enalapril group, the AUC(0-24h) was 704.53 +/- 158.86 and 4149.27 +/- 847.30 microg.h/L for the analytes enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],4149.27,102300,DB00435,Nitric Oxide
,27434056,Cmax,"One hour after ingestion (Tmax ), L-hArg increased the baseline L-hArg plasma concentration (2.87 ± 0.91 μmol l-1 , mean ± SD) by 8.74 ± 4.46 [95% confidence intervals 6.65; 10.9] and 17.3 ± 4.97 [14.9; 19.6] μmol l-1 (Cmax ), after single and multiple doses, respectively.",Oral supplementation with L-homoarginine in young volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434056/),,8.74,107184,DB00435,Nitric Oxide
,27434056,Cmax,"One hour after ingestion (Tmax ), L-hArg increased the baseline L-hArg plasma concentration (2.87 ± 0.91 μmol l-1 , mean ± SD) by 8.74 ± 4.46 [95% confidence intervals 6.65; 10.9] and 17.3 ± 4.97 [14.9; 19.6] μmol l-1 (Cmax ), after single and multiple doses, respectively.",Oral supplementation with L-homoarginine in young volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434056/),,17.3,107185,DB00435,Nitric Oxide
,27434056,AUCs0-24h,"Once-only and 4 weeks of supplementation resulted in AUCs0-24h of 63.5 ± 28.8 [50.0; 76.9] and 225 ± 78.5 [188; 2624] μmol l-1 *h, for single and multiple doses, respectively.",Oral supplementation with L-homoarginine in young volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434056/),[h·μM] / [l],63.5,107186,DB00435,Nitric Oxide
,27434056,AUCs0-24h,"Once-only and 4 weeks of supplementation resulted in AUCs0-24h of 63.5 ± 28.8 [50.0; 76.9] and 225 ± 78.5 [188; 2624] μmol l-1 *h, for single and multiple doses, respectively.",Oral supplementation with L-homoarginine in young volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434056/),[h·μM] / [l],225,107187,DB00435,Nitric Oxide
,8004383,half-lives,"Plasma L-NOARG concentrations declined biexponentially, with average half-lives of 11 min and 20 h.","Pharmacokinetics, plasma protein binding and urinary excretion of N omega-nitro-L-arginine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004383/),min,11,109249,DB00435,Nitric Oxide
,8004383,half-lives,"Plasma L-NOARG concentrations declined biexponentially, with average half-lives of 11 min and 20 h.","Pharmacokinetics, plasma protein binding and urinary excretion of N omega-nitro-L-arginine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004383/),h,20,109250,DB00435,Nitric Oxide
,11855749,bioavailability,"The pharmacokinetics of DMXAA in plasma, liver and tumour tissue indicated a bioavailability of 73%.","Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855749/),%,73,109267,DB00435,Nitric Oxide
,31814493,particle,"Results: The particle size, polydispersity index (PDI), and zeta potential of FF-NC were 276.4 ± 19.4 nm, 0.166 ± 0.011, and -18.66 ± 5.25 mV, respectively.",Increased bioaffinity and anti-inflammatory activity of florfenicol nanocrystals by wet grinding method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31814493/),nm,276.4,110909,DB00435,Nitric Oxide
,31814493,polydispersity index (PDI),"Results: The particle size, polydispersity index (PDI), and zeta potential of FF-NC were 276.4 ± 19.4 nm, 0.166 ± 0.011, and -18.66 ± 5.25 mV, respectively.",Increased bioaffinity and anti-inflammatory activity of florfenicol nanocrystals by wet grinding method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31814493/),mv,0.166,110910,DB00435,Nitric Oxide
,31814493,zeta potential,"Results: The particle size, polydispersity index (PDI), and zeta potential of FF-NC were 276.4 ± 19.4 nm, 0.166 ± 0.011, and -18.66 ± 5.25 mV, respectively.",Increased bioaffinity and anti-inflammatory activity of florfenicol nanocrystals by wet grinding method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31814493/),mv,-,110911,DB00435,Nitric Oxide
,31814493,zeta potential,"Results: The particle size, polydispersity index (PDI), and zeta potential of FF-NC were 276.4 ± 19.4 nm, 0.166 ± 0.011, and -18.66 ± 5.25 mV, respectively.",Increased bioaffinity and anti-inflammatory activity of florfenicol nanocrystals by wet grinding method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31814493/),mv,18.66,110912,DB00435,Nitric Oxide
,17192504,AUC(inf),"(S)-Warfarin AUC(inf) and t(1/2) were 106,471 h x microg/L and 82.92 hours versus 33,148 h x microg/L under HMR1766 and 31.72 hours under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% versus 39.94%.",Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192504/),[h·μg] / [l],"106,471",111837,DB00435,Nitric Oxide
,17192504,AUC(inf),"(S)-Warfarin AUC(inf) and t(1/2) were 106,471 h x microg/L and 82.92 hours versus 33,148 h x microg/L under HMR1766 and 31.72 hours under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% versus 39.94%.",Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192504/),[h·μg] / [l],"33,148",111838,DB00435,Nitric Oxide
,17192504,t(1/2),"(S)-Warfarin AUC(inf) and t(1/2) were 106,471 h x microg/L and 82.92 hours versus 33,148 h x microg/L under HMR1766 and 31.72 hours under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% versus 39.94%.",Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192504/),h,82.92,111839,DB00435,Nitric Oxide
,17192504,t(1/2),"(S)-Warfarin AUC(inf) and t(1/2) were 106,471 h x microg/L and 82.92 hours versus 33,148 h x microg/L under HMR1766 and 31.72 hours under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% versus 39.94%.",Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192504/),h,31.72,111840,DB00435,Nitric Oxide
,17044464,urate,"The MTACs of low molecular weight (LMW) solutes in the ISMN period were greater than the placebo period: median urea, 16.7 vs 13.8 ml/min; creatinine (Cr), 7.9 vs 6.9 ml/min; and urate, 6.1 vs 5.5 ml/min (p < 0.05 for all except MTAC of urea).",Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044464/),,5,112434,DB00435,Nitric Oxide
,17044464,net ultrafiltration (UF),"Despite the increased peritoneal solute clearance, net ultrafiltration (UF) was unchanged after drug administration, 110 (ISMN group) vs 120 ml (placebo group), (NS).",Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044464/),ml,110,112435,DB00435,Nitric Oxide
,17044464,net ultrafiltration (UF),"Despite the increased peritoneal solute clearance, net ultrafiltration (UF) was unchanged after drug administration, 110 (ISMN group) vs 120 ml (placebo group), (NS).",Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044464/),ml,120,112436,DB00435,Nitric Oxide
,9171941,Cl,The Cl increased from 0.028 L/min after the lower dose to 0.032 L/min after the higher dose.,Endotoxin alters the systemic disposition of nitric oxide synthase inhibitors in the awake sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9171941/),[l] / [min],0.028,112448,DB00435,Nitric Oxide
,9171941,Cl,The Cl increased from 0.028 L/min after the lower dose to 0.032 L/min after the higher dose.,Endotoxin alters the systemic disposition of nitric oxide synthase inhibitors in the awake sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9171941/),[l] / [min],0.032,112449,DB00435,Nitric Oxide
,9171941,Cl,"The infusion of endotoxin caused an increase in Cl of NOLA to 0.040 and 0.047 L/min, respectively, and a decrease in plasma slow half-life (t1/2) from 825 to 546 min and from 780 to 453 min, respectively.",Endotoxin alters the systemic disposition of nitric oxide synthase inhibitors in the awake sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9171941/),[l] / [min],0.040,112450,DB00435,Nitric Oxide
,9171941,Cl,"The infusion of endotoxin caused an increase in Cl of NOLA to 0.040 and 0.047 L/min, respectively, and a decrease in plasma slow half-life (t1/2) from 825 to 546 min and from 780 to 453 min, respectively.",Endotoxin alters the systemic disposition of nitric oxide synthase inhibitors in the awake sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9171941/),[l] / [min],0.047,112451,DB00435,Nitric Oxide
,9171941,plasma slow half-life (t1/2),"The infusion of endotoxin caused an increase in Cl of NOLA to 0.040 and 0.047 L/min, respectively, and a decrease in plasma slow half-life (t1/2) from 825 to 546 min and from 780 to 453 min, respectively.",Endotoxin alters the systemic disposition of nitric oxide synthase inhibitors in the awake sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9171941/),min,82,112452,DB00435,Nitric Oxide
,9171941,plasma slow half-life (t1/2),"The infusion of endotoxin caused an increase in Cl of NOLA to 0.040 and 0.047 L/min, respectively, and a decrease in plasma slow half-life (t1/2) from 825 to 546 min and from 780 to 453 min, respectively.",Endotoxin alters the systemic disposition of nitric oxide synthase inhibitors in the awake sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9171941/),min,780 to 453,112453,DB00435,Nitric Oxide
,9171941,half-life,4. NL-Nitro-L-arginine methylester was rapidly cleared from the plasma with a slow half-life of approximately 7.5 min and there was a simultaneous appearance of NOLA in the plasma.,Endotoxin alters the systemic disposition of nitric oxide synthase inhibitors in the awake sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9171941/),min,7.5,112454,DB00435,Nitric Oxide
,10082193,ED50,The ED50 value of ethosuximide was significantly increased from 108 to 158 mg/kg.,N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082193/),[mg] / [kg],108,114767,DB00435,Nitric Oxide
,10082193,ED50,The ED50 value of ethosuximide was significantly increased from 108 to 158 mg/kg.,N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082193/),[mg] / [kg],158,114768,DB00435,Nitric Oxide
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],84.25,118464,DB00435,Nitric Oxide
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],47.40,118465,DB00435,Nitric Oxide
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],653.67,118466,DB00435,Nitric Oxide
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],182.26,118467,DB00435,Nitric Oxide
,17662768,circulating plasma c,"Based on our previous work, the target circulating plasma citrulline trough was 80 to 100 micromol/L.",Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17662768/),[μM] / [l],80 to 100,118542,DB00435,Nitric Oxide
,17662768,trough level,The initial stepwise escalation protocol (phase 1) revealed that an intravenous citrulline dose of 150 mg/kg given after initiation of cardiopulmonary bypass yielded a trough level of in the target range of approximately 80 to 100 micromol/L 4 hours later.,Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17662768/),[μM] / [l],80 to 100,118543,DB00435,Nitric Oxide
,17662768,clearance,"The postoperative dose revealed that the clearance of intravenously administered citrulline was 0.6 L/(h.kg), with a volume of distribution of 0.9 L/kg and estimated half-life of 60 minutes.",Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17662768/),[l] / [h·kg],0.6,118544,DB00435,Nitric Oxide
,17662768,volume of distribution,"The postoperative dose revealed that the clearance of intravenously administered citrulline was 0.6 L/(h.kg), with a volume of distribution of 0.9 L/kg and estimated half-life of 60 minutes.",Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17662768/),[l] / [kg],0.9,118545,DB00435,Nitric Oxide
,17662768,half-life,"The postoperative dose revealed that the clearance of intravenously administered citrulline was 0.6 L/(h.kg), with a volume of distribution of 0.9 L/kg and estimated half-life of 60 minutes.",Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17662768/),min,60,118546,DB00435,Nitric Oxide
,17662768,clearance,"Mean plasma citrulline levels were maintained at approximately 125 mumol/L, with a calculated clearance of 0.52 L/(h.kg).",Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17662768/),[l] / [h·kg],0.52,118547,DB00435,Nitric Oxide
,15900289,maximal,"Urinary sodium excretion was reduced in all active treatment groups (maximal reduction of approximately 11 mmol/h during normal sodium intake, P < .05 versus placebo for all groups).",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),,11,120422,DB00435,Nitric Oxide
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],28.1,120423,DB00435,Nitric Oxide
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],33.7,120424,DB00435,Nitric Oxide
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],25.2,120425,DB00435,Nitric Oxide
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],41.7,120426,DB00435,Nitric Oxide
,9550632,absolute sodium excretion,"Large decreases in absolute sodium excretion, from 79+/-10 to 34+/-5 micromol/min (P<0.01), and fractional sodium excretion, from 0.5+/-0.0 to 0.3+/-0.0% (P<0.01), were associated with significant reductions in fractional lithium excretion (P<0.05) and maximum urine flow (P<0.01).",Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),[μM] / [min],79,121918,DB00435,Nitric Oxide
,9550632,absolute sodium excretion,"Large decreases in absolute sodium excretion, from 79+/-10 to 34+/-5 micromol/min (P<0.01), and fractional sodium excretion, from 0.5+/-0.0 to 0.3+/-0.0% (P<0.01), were associated with significant reductions in fractional lithium excretion (P<0.05) and maximum urine flow (P<0.01).",Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),[μM] / [min],34,121919,DB00435,Nitric Oxide
,9550632,fractional sodium excretion,"Large decreases in absolute sodium excretion, from 79+/-10 to 34+/-5 micromol/min (P<0.01), and fractional sodium excretion, from 0.5+/-0.0 to 0.3+/-0.0% (P<0.01), were associated with significant reductions in fractional lithium excretion (P<0.05) and maximum urine flow (P<0.01).",Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),%,0.5,121920,DB00435,Nitric Oxide
,9550632,fractional sodium excretion,"Large decreases in absolute sodium excretion, from 79+/-10 to 34+/-5 micromol/min (P<0.01), and fractional sodium excretion, from 0.5+/-0.0 to 0.3+/-0.0% (P<0.01), were associated with significant reductions in fractional lithium excretion (P<0.05) and maximum urine flow (P<0.01).",Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),%,0.3,121921,DB00435,Nitric Oxide
,9550632,Minimal urine sodium concentration,Minimal urine sodium concentration decreased from 5.8+/-0.04 to 3.9+/-0.4 mmol/l (P<0.01) whereas minimal urine osmolality increased (P<0.05).,Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),[mM] / [l],5.8,121922,DB00435,Nitric Oxide
,9550632,Minimal urine sodium concentration,Minimal urine sodium concentration decreased from 5.8+/-0.04 to 3.9+/-0.4 mmol/l (P<0.01) whereas minimal urine osmolality increased (P<0.05).,Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),[mM] / [l],3.9,121923,DB00435,Nitric Oxide
,9688061,"half-time (t1/2,keo)","Using nonparametric analysis, the equilibration half-time (t1/2,keo) between plasma L-NA and the hypothetical effect site was determined to be 51.5 +/- 6.6 min, 42.4 +/- 10.1 min, 43.4 +/- 9.0 min for MAP, CI, and SVR, respectively (n = 14).",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),min,51.5,122163,DB00435,Nitric Oxide
,9688061,"half-time (t1/2,keo)","Using nonparametric analysis, the equilibration half-time (t1/2,keo) between plasma L-NA and the hypothetical effect site was determined to be 51.5 +/- 6.6 min, 42.4 +/- 10.1 min, 43.4 +/- 9.0 min for MAP, CI, and SVR, respectively (n = 14).",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),min,42.4,122164,DB00435,Nitric Oxide
,9688061,"half-time (t1/2,keo)","Using nonparametric analysis, the equilibration half-time (t1/2,keo) between plasma L-NA and the hypothetical effect site was determined to be 51.5 +/- 6.6 min, 42.4 +/- 10.1 min, 43.4 +/- 9.0 min for MAP, CI, and SVR, respectively (n = 14).",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),min,43.4,122165,DB00435,Nitric Oxide
,9688061,Emax,"The Emax and EC50 values obtained were + 32.5 +/- 8.4 and 2.6 +/- 1.3 microg/ml for MAP and -52.9 +/- 15.6 and 3.7 +/- 1.8 microg/ml for CI, respectively.",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),[μg] / [ml],+,122166,DB00435,Nitric Oxide
,9688061,Emax,"The Emax and EC50 values obtained were + 32.5 +/- 8.4 and 2.6 +/- 1.3 microg/ml for MAP and -52.9 +/- 15.6 and 3.7 +/- 1.8 microg/ml for CI, respectively.",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),[μg] / [ml],32.5,122167,DB00435,Nitric Oxide
,9688061,Emax,"The Emax and EC50 values obtained were + 32.5 +/- 8.4 and 2.6 +/- 1.3 microg/ml for MAP and -52.9 +/- 15.6 and 3.7 +/- 1.8 microg/ml for CI, respectively.",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),[μg] / [ml],-52.9,122168,DB00435,Nitric Oxide
,9688061,EC50,"The Emax and EC50 values obtained were + 32.5 +/- 8.4 and 2.6 +/- 1.3 microg/ml for MAP and -52.9 +/- 15.6 and 3.7 +/- 1.8 microg/ml for CI, respectively.",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),[μg] / [ml],32.5,122169,DB00435,Nitric Oxide
,9688061,EC50,"The Emax and EC50 values obtained were + 32.5 +/- 8.4 and 2.6 +/- 1.3 microg/ml for MAP and -52.9 +/- 15.6 and 3.7 +/- 1.8 microg/ml for CI, respectively.",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),[μg] / [ml],2.6,122170,DB00435,Nitric Oxide
,9688061,EC50,"The Emax and EC50 values obtained were + 32.5 +/- 8.4 and 2.6 +/- 1.3 microg/ml for MAP and -52.9 +/- 15.6 and 3.7 +/- 1.8 microg/ml for CI, respectively.",Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688061/),[μg] / [ml],3.7,122171,DB00435,Nitric Oxide
,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,50-400,122850,DB00435,Nitric Oxide
>,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,"15,000",122851,DB00435,Nitric Oxide
≤,21036913,minimal effective dose,KLYP961 also attenuated capsaicin-induced thermal allodynia in rhesus primates in a dose-related manner with a minimal effective dose (≤ 10 mg/kg p.o.) and a greater potency than gabapentin.,"Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),mg,10,122852,DB00435,Nitric Oxide
,17267147,penetration rate constants,"The in vitro transdermal penetration of both ISDN and BP from the patches displayed a zero-order process, and the penetration rate constants were 7.4 microg/(cm(2)h) for ISDN, and 5.9 microg/(cm(2)h) for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),[μg] / [cm(2)h],7.4,123504,DB00435,Nitric Oxide
,17267147,penetration rate constants,"The in vitro transdermal penetration of both ISDN and BP from the patches displayed a zero-order process, and the penetration rate constants were 7.4 microg/(cm(2)h) for ISDN, and 5.9 microg/(cm(2)h) for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),[μg] / [cm(2)h],5.9,123505,DB00435,Nitric Oxide
,17267147,absolute bioavailabilities,"After transdermal administration to rabbits, the absolute bioavailabilities were 33.6% for ISDN, and 31.3% for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),%,33.6,123506,DB00435,Nitric Oxide
,17267147,absolute bioavailabilities,"After transdermal administration to rabbits, the absolute bioavailabilities were 33.6% for ISDN, and 31.3% for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),%,31.3,123507,DB00435,Nitric Oxide
,24795884,AUC,"We observed a significant reduction in WW (P < 0.001), W/L (P < 0.05), and MCSA (P < 0.01) and improved endothelium-dependent relaxation (AUC(SHR-E) = 201.2 ± 33 versus AUC(SHR) = 97.5 ± 21, P < 0.05) in SHR-E compared with untreated SHR; no differences were observed for WW, MCSA, and endothelium-dependent relaxation by ACh at higher concentrations (10(-6) to 10(-4) mol/l) for SHR-E with respect to WKY.",Short-term esmolol improves coronary artery remodeling in spontaneously hypertensive rats through increased nitric oxide bioavailability and superoxide dismutase activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24795884/),,201.2,124211,DB00435,Nitric Oxide
,24795884,AUC,"We observed a significant reduction in WW (P < 0.001), W/L (P < 0.05), and MCSA (P < 0.01) and improved endothelium-dependent relaxation (AUC(SHR-E) = 201.2 ± 33 versus AUC(SHR) = 97.5 ± 21, P < 0.05) in SHR-E compared with untreated SHR; no differences were observed for WW, MCSA, and endothelium-dependent relaxation by ACh at higher concentrations (10(-6) to 10(-4) mol/l) for SHR-E with respect to WKY.",Short-term esmolol improves coronary artery remodeling in spontaneously hypertensive rats through increased nitric oxide bioavailability and superoxide dismutase activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24795884/),,97.5,124212,DB00435,Nitric Oxide
,16526822,bioavailability,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),,0,125650,DB00435,Nitric Oxide
,16526822,50%Maximum plasma concentration,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[μg] / [l],0.1 to >1,125651,DB00435,Nitric Oxide
,16526822,Volume of distribution,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[μg] / [l],0.1 to >1,125652,DB00435,Nitric Oxide
,16526822,Volume of distribution,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[l] / [kg],3,125653,DB00435,Nitric Oxide
,16526822,Clearance,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[l] / [kg],3,125654,DB00435,Nitric Oxide
,16526822,Clearance,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[l] / [kg·min],1,125655,DB00435,Nitric Oxide
,16526822,Elimination half-life,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[l] / [kg·min],1,125656,DB00435,Nitric Oxide
,16526822,Elimination half-life,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),min,3,125657,DB00435,Nitric Oxide
,14660179,Cmax of radioactivity,"2. The dose of [14C]L-NIL-TA was rapidly absorbed and distributed after oral and intravenous administration (5 mg kg-1), with Cmax of radioactivity of 6.45-7.07 microg equivalents g-1 occurring at 0.33-0.39-h after dosing.","Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14660179/),[equivalents·μg] / [g],6.45-7.07,131395,DB00435,Nitric Oxide
,14660179,half-life,"After oral and intravenous administration, radioactivity levels in plasma then declined with a half-life of 63.1 and 80.6-h, respectively.","Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14660179/),h,63.1,131396,DB00435,Nitric Oxide
,14660179,half-life,"After oral and intravenous administration, radioactivity levels in plasma then declined with a half-life of 63.1 and 80.6-h, respectively.","Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14660179/),h,80.6,131397,DB00435,Nitric Oxide
,14660179,total recovery of radioactivity,The mean total recovery of radioactivity over 7 days was approximately 80%.,"Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14660179/),%,80,131398,DB00435,Nitric Oxide
,15224134,IC50,Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC50 of 0.7 nM.,"Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),nM,0.7,138838,DB00435,Nitric Oxide
,15224134,Tmax,"Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (Tmax=1 h; T1/2=1.2 h), although erectile effects have been observed after 7 h.","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,1,138839,DB00435,Nitric Oxide
,15224134,T1/2,"Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (Tmax=1 h; T1/2=1.2 h), although erectile effects have been observed after 7 h.","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,1.2,138840,DB00435,Nitric Oxide
,15224134,Tmax,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),min,40,138841,DB00435,Nitric Oxide
,15224134,T1/2,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,4,138842,DB00435,Nitric Oxide
,15224134,absolute bioavailability,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),%,14.5,138843,DB00435,Nitric Oxide
,15224134,absolute bioavailability,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),%,40,138844,DB00435,Nitric Oxide
,12504938,final levels,"Serum levels of isosorbide mononitrate continued to rise up to 360 minutes after isosorbide mononitrate insertion, with mean (SD) final levels of 337 (94) microg/L following isosorbide mononitrate 40 mg and 144 (47) microg/L following isosorbide mononitrate 20 mg, P < 0.01.",Serum profile of isosorbide mononitrate after vaginal administration in the third trimester. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504938/),[μg] / [l],337,145073,DB00435,Nitric Oxide
,12504938,final levels,"Serum levels of isosorbide mononitrate continued to rise up to 360 minutes after isosorbide mononitrate insertion, with mean (SD) final levels of 337 (94) microg/L following isosorbide mononitrate 40 mg and 144 (47) microg/L following isosorbide mononitrate 20 mg, P < 0.01.",Serum profile of isosorbide mononitrate after vaginal administration in the third trimester. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504938/),[μg] / [l],144,145074,DB00435,Nitric Oxide
,33744327,Feno,Mean Feno at baseline across all subjects was 93 ± 43 ppb.,"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33744327/),ppb,93,146658,DB00435,Nitric Oxide
,27093249,half-life,A half-life of 40.63 ± 6.66 min and a clearance of 1.00 ± 0.36 L/h/kg were found in the in vivo pharmacokinetic study.,Pharmacokinetics and In Vitro Blood-Brain Barrier Screening of the Plant-Derived Alkaloid Tryptanthrin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27093249/),min,40.63,147611,DB00435,Nitric Oxide
,27093249,clearance,A half-life of 40.63 ± 6.66 min and a clearance of 1.00 ± 0.36 L/h/kg were found in the in vivo pharmacokinetic study.,Pharmacokinetics and In Vitro Blood-Brain Barrier Screening of the Plant-Derived Alkaloid Tryptanthrin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27093249/),[l] / [h·kg],1.00,147612,DB00435,Nitric Oxide
below,27093249,efflux ratio,An efflux ratio below 2 indicated that tryptanthrin is not subjected to active efflux.,Pharmacokinetics and In Vitro Blood-Brain Barrier Screening of the Plant-Derived Alkaloid Tryptanthrin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27093249/),,2,147613,DB00435,Nitric Oxide
,16597076,forced expiratory volume in 1 second,"Fifteen asthmatic patients (mean +/- SEM forced expiratory volume in 1 second [FEV1], 2.62 +/- 0.21 L; provocative concentration of methacholine causing a 20% decrease in FEV1 [PC20], 1.06 +/- 0.58) were randomized to completion in a placebo-controlled, double-blind, crossover manner to receive Beclate or Qvar at doses of 100 or 400 microg/d for 2 weeks, with a 1-week washout period before each randomized treatment.",A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16597076/),l,2.62,149135,DB00435,Nitric Oxide
,23944041,EC50,"The EC50 for antipyretic effect and decrease of plasma NO concentration was respectively equal to 114.1, 90.80 microg x L(-1).",[Pharmacokinetic/pharmacodynamic modeling of antipyretic and reducing plasma concentration of NO effects of Rheum palmatum in rat]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944041/),[μg] / [l],114.1,149486,DB00435,Nitric Oxide
,23944041,EC50,"The EC50 for antipyretic effect and decrease of plasma NO concentration was respectively equal to 114.1, 90.80 microg x L(-1).",[Pharmacokinetic/pharmacodynamic modeling of antipyretic and reducing plasma concentration of NO effects of Rheum palmatum in rat]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944041/),[μg] / [l],90.80,149487,DB00435,Nitric Oxide
,18838585,clearance,"A two-compartment linear model with first-order elimination best described the data, with a clearance of 44 liters/h (coefficient of variation [CV] = 52%) and a volume of distribution of 24 liters (CV = 19%).",Pharmacokinetics of L-arginine in adults with moderately severe malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18838585/),[l] / [h],44,151903,DB00435,Nitric Oxide
,18838585,volume of distribution,"A two-compartment linear model with first-order elimination best described the data, with a clearance of 44 liters/h (coefficient of variation [CV] = 52%) and a volume of distribution of 24 liters (CV = 19%).",Pharmacokinetics of L-arginine in adults with moderately severe malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18838585/),l,24,151904,DB00435,Nitric Oxide
,18838585,time to half recovery,The natural time course of L-arginine recovery was described empirically by a second-order polynomial with a time to half recovery of 26 h.,Pharmacokinetics of L-arginine in adults with moderately severe malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18838585/),h,26,151905,DB00435,Nitric Oxide
,24177023,mean residence time,"After a bolus i.v. injection, the elimination of nor-NOHA was rapid (the mean residence time was 12.5 min).","Single- and multiple-dose pharmacokinetics of arginase inhibitor Nω-hydroxy-nor-L-arginine, and its effect on plasma amino acids concentrations in Wistar rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24177023/),min,12.5,154172,DB00435,Nitric Oxide
,8842573,urinary excretion,The urinary excretion of nitrate during nitrate restriction was 840 +/- 146 mumol/24 h.,Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842573/),[μM] / [24·h],840,157246,DB00435,Nitric Oxide
,8842573,t1/2,"The subsequent drop in plasma nitrate, with a t1/2 of 451 +/- 42 min, was probably a reflection of the redistribution of nitrate within the body fluids and the renal excretion of nitrate.",Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842573/),min,451,157247,DB00435,Nitric Oxide
,8842573,plasma clearance,The plasma clearance of nitrate was 30 +/- 2 ml/min/1.73 m2 BSA.,Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842573/),[ml] / [1.73·m2·min],30,157248,DB00435,Nitric Oxide
,12734607,residual m,"The highest average concentration in molsidomine and SIN-1 occurred after 6 h, then a plateau of 15-20 ng/ml molsidomine and 0.8-3.0 ng/ml SIN-1 was maintained for at least 8 h and the mean residual molsidomine concentration 24 h post-drug intake was around 8 ng/ml, still in the effective range of 5-10 ng/ml.",A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12734607/),[ng] / [ml],8,162356,DB00435,Nitric Oxide
,16257402,compliance,"In conscious pigs, instrumented with a fundic cannula, L-NAME (20 mg/kg i.v.) significantly increased mean arterial blood pressure and decreased fundic compliance in the fasted state (71+/-13 ml/mm Hg versus 185+/-37 ml/mm Hg after saline; P<0.05).",Influence of the selective neuronal NO synthase inhibitor ARL 17477 on nitrergic neurotransmission in porcine stomach. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257402/),[ml] / [hg·mm],71,165160,DB00435,Nitric Oxide
,16257402,compliance,"In conscious pigs, instrumented with a fundic cannula, L-NAME (20 mg/kg i.v.) significantly increased mean arterial blood pressure and decreased fundic compliance in the fasted state (71+/-13 ml/mm Hg versus 185+/-37 ml/mm Hg after saline; P<0.05).",Influence of the selective neuronal NO synthase inhibitor ARL 17477 on nitrergic neurotransmission in porcine stomach. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257402/),[ml] / [hg·mm],185,165161,DB00435,Nitric Oxide
less,16257402,half-life,Plasma concentration analysis of ARL 17477 indicated a half-life of less than 30 min in pig.,Influence of the selective neuronal NO synthase inhibitor ARL 17477 on nitrergic neurotransmission in porcine stomach. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257402/),min,30,165162,DB00435,Nitric Oxide
,32314550,Plasma Tmax,Plasma Tmax was 1 hour and the t1/2 of total plasma radioactivity was 23.7 hours.,"Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32314550/),h,1,168415,DB00435,Nitric Oxide
,32314550,t1/2,Plasma Tmax was 1 hour and the t1/2 of total plasma radioactivity was 23.7 hours.,"Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32314550/),h,23.7,168416,DB00435,Nitric Oxide
,32314550,cumulative recovery,"Mean cumulative recovery of the administered radioactivity in urine and feces over 168 hours was 3.7% and 95.7%, respectively.","Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32314550/),%,3.7,168417,DB00435,Nitric Oxide
,32314550,cumulative recovery,"Mean cumulative recovery of the administered radioactivity in urine and feces over 168 hours was 3.7% and 95.7%, respectively.","Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32314550/),%,95.7,168418,DB00435,Nitric Oxide
,15943756,E(max) Control,The reactivity to phenylephrine increased in the L-NAME group (E(max) Control: 2.00+/-0.15 g versus L-NAME: 2.45+/-0.14 g); tempol+L-NAME (E(max): 2.55+/-0.15 g) and in the tempol group (E(max): 2.57+/-0.14 g).,"The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943756/),g,2.00,169860,DB00435,Nitric Oxide
,15943756,E(max) Control,The reactivity to phenylephrine increased in the L-NAME group (E(max) Control: 2.00+/-0.15 g versus L-NAME: 2.45+/-0.14 g); tempol+L-NAME (E(max): 2.55+/-0.15 g) and in the tempol group (E(max): 2.57+/-0.14 g).,"The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943756/),g,2.45,169861,DB00435,Nitric Oxide
,15943756,E(max),The reactivity to phenylephrine increased in the L-NAME group (E(max) Control: 2.00+/-0.15 g versus L-NAME: 2.45+/-0.14 g); tempol+L-NAME (E(max): 2.55+/-0.15 g) and in the tempol group (E(max): 2.57+/-0.14 g).,"The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943756/),g,2.55,169862,DB00435,Nitric Oxide
,15943756,E(max),The reactivity to phenylephrine increased in the L-NAME group (E(max) Control: 2.00+/-0.15 g versus L-NAME: 2.45+/-0.14 g); tempol+L-NAME (E(max): 2.55+/-0.15 g) and in the tempol group (E(max): 2.57+/-0.14 g).,"The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943756/),g,2.57,169863,DB00435,Nitric Oxide
,15943756,Maximal relaxation,Maximal relaxation induced by acetylcholine was reduced in L-NAME group (60.9+/-3%) and tempol+L-NAME (37.4+/-6%) compared to Control (99.1+/-0.12%) and tempol groups (95.6+/-2.12%).,"The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943756/),%,60.9,169864,DB00435,Nitric Oxide
,15943756,Maximal relaxation,Maximal relaxation induced by acetylcholine was reduced in L-NAME group (60.9+/-3%) and tempol+L-NAME (37.4+/-6%) compared to Control (99.1+/-0.12%) and tempol groups (95.6+/-2.12%).,"The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943756/),%,37.4,169865,DB00435,Nitric Oxide
,15943756,Maximal relaxation,Maximal relaxation induced by acetylcholine was reduced in L-NAME group (60.9+/-3%) and tempol+L-NAME (37.4+/-6%) compared to Control (99.1+/-0.12%) and tempol groups (95.6+/-2.12%).,"The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943756/),%,99.1,169866,DB00435,Nitric Oxide
,15943756,Maximal relaxation,Maximal relaxation induced by acetylcholine was reduced in L-NAME group (60.9+/-3%) and tempol+L-NAME (37.4+/-6%) compared to Control (99.1+/-0.12%) and tempol groups (95.6+/-2.12%).,"The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943756/),%,95.6,169867,DB00435,Nitric Oxide
,11141091,oral bioavailability,Pharmacokinetic studies in rats showed that compound 32 exhibits modest oral bioavailability (12%).,"Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11141091/),%,12,170215,DB00435,Nitric Oxide
,20959430,excretion,"In healthy subjects, both nitrate and cGMP excretion were higher following L-arginine compared to placebo infusion: 132.63 (100.24, 165.02) versus 92.07 (66.33, 117.82) µmol/mmol creatinine for nitrate (P=0.014) and 50.53 (42.19, 58.87) versus 39.64 (33.94, 45.34) nmol/mmol creatinine for cGMP (P=0.0003), respectively.",No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959430/),[μM] / [mM],132.63,171301,DB00435,Nitric Oxide
,20959430,excretion,"In healthy subjects, both nitrate and cGMP excretion were higher following L-arginine compared to placebo infusion: 132.63 (100.24, 165.02) versus 92.07 (66.33, 117.82) µmol/mmol creatinine for nitrate (P=0.014) and 50.53 (42.19, 58.87) versus 39.64 (33.94, 45.34) nmol/mmol creatinine for cGMP (P=0.0003), respectively.",No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959430/),[μM] / [mM],92.07,171302,DB00435,Nitric Oxide
,20959430,excretion,"In healthy subjects, both nitrate and cGMP excretion were higher following L-arginine compared to placebo infusion: 132.63 (100.24, 165.02) versus 92.07 (66.33, 117.82) µmol/mmol creatinine for nitrate (P=0.014) and 50.53 (42.19, 58.87) versus 39.64 (33.94, 45.34) nmol/mmol creatinine for cGMP (P=0.0003), respectively.",No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959430/),[nM] / [mM],50.53,171303,DB00435,Nitric Oxide
,20959430,excretion,"In healthy subjects, both nitrate and cGMP excretion were higher following L-arginine compared to placebo infusion: 132.63 (100.24, 165.02) versus 92.07 (66.33, 117.82) µmol/mmol creatinine for nitrate (P=0.014) and 50.53 (42.19, 58.87) versus 39.64 (33.94, 45.34) nmol/mmol creatinine for cGMP (P=0.0003), respectively.",No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959430/),[nM] / [mM],39.64,171304,DB00435,Nitric Oxide
,29223585,peak increases,The peak increases in plasma [NO2-] were greater in BF (371 ± 136 nM) and BR (369 ± 167 nM) compared to BL (283 ± 93 nM; all P<0.05) and BC (232 ± 51 nM).,Influence of dietary nitrate food forms on nitrate metabolism and blood pressure in healthy normotensive adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223585/),nM,371,171590,DB00435,Nitric Oxide
,29223585,peak increases,The peak increases in plasma [NO2-] were greater in BF (371 ± 136 nM) and BR (369 ± 167 nM) compared to BL (283 ± 93 nM; all P<0.05) and BC (232 ± 51 nM).,Influence of dietary nitrate food forms on nitrate metabolism and blood pressure in healthy normotensive adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223585/),nM,369,171591,DB00435,Nitric Oxide
,29223585,peak increases,The peak increases in plasma [NO2-] were greater in BF (371 ± 136 nM) and BR (369 ± 167 nM) compared to BL (283 ± 93 nM; all P<0.05) and BC (232 ± 51 nM).,Influence of dietary nitrate food forms on nitrate metabolism and blood pressure in healthy normotensive adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223585/),nM,283,171592,DB00435,Nitric Oxide
,29223585,peak increases,The peak increases in plasma [NO2-] were greater in BF (371 ± 136 nM) and BR (369 ± 167 nM) compared to BL (283 ± 93 nM; all P<0.05) and BC (232 ± 51 nM).,Influence of dietary nitrate food forms on nitrate metabolism and blood pressure in healthy normotensive adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223585/),nM,232,171593,DB00435,Nitric Oxide
,23541649,half-life,"Compound 16, with a suitable half-life (17.8 min) in PBS at pH 7, released NO (19%) and HNO (22%) during a 2h incubation in PBS at pH 7.","A diazen-1-ium-1,2-diolate analog of 7-azabenzobicyclo[2.2.1]heptane: synthesis, nitric oxide and nitroxyl release, in vitro hemodynamic, and anti-hypertensive studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541649/),min,17.8,171598,DB00435,Nitric Oxide
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],878.50,172791,DB00435,Nitric Oxide
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],"1,994.04",172792,DB00435,Nitric Oxide
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],314.82,172793,DB00435,Nitric Oxide
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],"1,314.12",172794,DB00435,Nitric Oxide
,10024078,plasma,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],786.04,172795,DB00435,Nitric Oxide
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],786.04,172796,DB00435,Nitric Oxide
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],960.04,172797,DB00435,Nitric Oxide
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],474.55,172798,DB00435,Nitric Oxide
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],490.82,172799,DB00435,Nitric Oxide
,8690793,half-life,The half-life of DTPA iron (III) was 51 +/- 9 min in normal baboons; primary clearance was consistent with glomerular filtration.,Efficacy of treatment with the iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherichia coli. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690793/),min,51,173864,DB00435,Nitric Oxide
<,30340896,IC50s,"Many potent inhibitors (30, 39, 41, 42, 44, 45 and 58) were identified with low nanomolar activity (IC50s: <15 nM) along with adequate metabolic stability.","Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340896/),nM,15,173996,DB00435,Nitric Oxide
,21083061,T(1/2),"In this mouse study, the T(1/2) of BH4 in plasma was approximately 1.2 h.",Detection of tetrahydrobiopterin by LC-MS/MS in plasma from multiple species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083061/),h,1.2,175144,DB00435,Nitric Oxide
,31513867,absolute bioavailability,Absorption of inhaled nitrite was rapid with the absolute bioavailability of 18%.,Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31513867/),%,18,175882,DB00435,Nitric Oxide
,31513867,clearance (CL),"In whole blood, nitrite exhibited the dose-independent pharmacokinetics with clearance (CL) of 1.5 l/h/kg, volume of distribution (Vd) of 1.3 l/kg and half-life (t1/2) of 0.6 h.",Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31513867/),[l] / [h·kg],1.5,175883,DB00435,Nitric Oxide
,31513867,volume of distribution (Vd),"In whole blood, nitrite exhibited the dose-independent pharmacokinetics with clearance (CL) of 1.5 l/h/kg, volume of distribution (Vd) of 1.3 l/kg and half-life (t1/2) of 0.6 h.",Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31513867/),[l] / [kg],1.3,175884,DB00435,Nitric Oxide
,31513867,half-life (t1/2),"In whole blood, nitrite exhibited the dose-independent pharmacokinetics with clearance (CL) of 1.5 l/h/kg, volume of distribution (Vd) of 1.3 l/kg and half-life (t1/2) of 0.6 h.",Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31513867/),h,0.6,175885,DB00435,Nitric Oxide
,28209351,AUC,"Regarding to the nebivolol glucuronide isomers, higher plasma concentrations of the d-isomer were observed compared to the l-isomer (d/l AUC=5.4), explaining at least in part the plasma accumulation of unchanged l-nebivolol (l/d AUC=1.8).",An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,5.4,179615,DB00435,Nitric Oxide
,28209351,AUC,"Regarding to the nebivolol glucuronide isomers, higher plasma concentrations of the d-isomer were observed compared to the l-isomer (d/l AUC=5.4), explaining at least in part the plasma accumulation of unchanged l-nebivolol (l/d AUC=1.8).",An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,1.8,179616,DB00435,Nitric Oxide
,28209351,ratios,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,6.5,179617,DB00435,Nitric Oxide
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],65.3,179618,DB00435,Nitric Oxide
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],10.1,179619,DB00435,Nitric Oxide
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],62.1,179620,DB00435,Nitric Oxide
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],335.2,179621,DB00435,Nitric Oxide
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],5.4,179622,DB00435,Nitric Oxide
,12028666,terminal half-life,The terminal half-life was 9.4 min and the mean residence time was 3.4 min.,Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12028666/),min,9.4,181590,DB00435,Nitric Oxide
,12028666,mean residence time,The terminal half-life was 9.4 min and the mean residence time was 3.4 min.,Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12028666/),min,3.4,181591,DB00435,Nitric Oxide
,12028666,terminal half-life,Levels then declined with a terminal half-life of 11.7 min.,Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12028666/),min,11.7,181592,DB00435,Nitric Oxide
,12028666,bioavailable fraction,"The bioavailable fraction from the i.p. compartment was 19%, indicating a high first-pass effect.",Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12028666/),%,19,181593,DB00435,Nitric Oxide
,10336578,maximum plasma concentration,Bolus infusion of L-NMMA resulted in a maximum plasma concentration of 12. 9+/-3.4 microg ml-1 (mean+/-s.d.) with elimination half-life of 63.,Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336578/),[μg] / [ml],12. 9,182460,DB00435,Nitric Oxide
,10336578,elimination half-life,Bolus infusion of L-NMMA resulted in a maximum plasma concentration of 12. 9+/-3.4 microg ml-1 (mean+/-s.d.) with elimination half-life of 63.,Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336578/),,63,182461,DB00435,Nitric Oxide
,10336578,clearance,"5+/-14.5 min and clearance of 12.2+/-3.5 ml min-1 kg-1 and caused a small hypertensive response, decreased CO by 13%, FPA by 26%, exhNO by 46% and increased systemic vascular resistance by 16% (P<0.05 each) 15 min after start of drug administration.",Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336578/),[ml] / [kg·min],12.2,182462,DB00435,Nitric Oxide
,27779776,AUC∞,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),[h·ng] / [ml],537,182986,DB00435,Nitric Oxide
,27779776,Cmax,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),[ng] / [ml],189.4,182987,DB00435,Nitric Oxide
,27779776,t1/2,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),h,10.5,182988,DB00435,Nitric Oxide
,31806398,IC50,"The IC50 values of compounds 7, 12 and 13 were 42.81, 20.55 and 22.74 μM.",Simultaneous characterisation of multiple Mahonia fortunei bioactive compounds in rat plasma by UPLC-MS/MS for application in pharmacokinetic studies and anti-inflammatory activity in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806398/),μM,42.81,183442,DB00435,Nitric Oxide
,31806398,IC50,"The IC50 values of compounds 7, 12 and 13 were 42.81, 20.55 and 22.74 μM.",Simultaneous characterisation of multiple Mahonia fortunei bioactive compounds in rat plasma by UPLC-MS/MS for application in pharmacokinetic studies and anti-inflammatory activity in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806398/),μM,20.55,183443,DB00435,Nitric Oxide
,31806398,IC50,"The IC50 values of compounds 7, 12 and 13 were 42.81, 20.55 and 22.74 μM.",Simultaneous characterisation of multiple Mahonia fortunei bioactive compounds in rat plasma by UPLC-MS/MS for application in pharmacokinetic studies and anti-inflammatory activity in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806398/),μM,22.74,183444,DB00435,Nitric Oxide
,16997910,IC50,AcEGCG exhibited enhanced growth inhibitory activity relative to EGCG in both KYSE150 human esophageal (IC50 = 10 versus 20 microM) and HCT116 human colon cancer cells (IC50 = 32 versus 45 microM).,Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997910/),μM,10,184266,DB00435,Nitric Oxide
,16997910,IC50,AcEGCG exhibited enhanced growth inhibitory activity relative to EGCG in both KYSE150 human esophageal (IC50 = 10 versus 20 microM) and HCT116 human colon cancer cells (IC50 = 32 versus 45 microM).,Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997910/),μM,20,184267,DB00435,Nitric Oxide
,16997910,IC50,AcEGCG exhibited enhanced growth inhibitory activity relative to EGCG in both KYSE150 human esophageal (IC50 = 10 versus 20 microM) and HCT116 human colon cancer cells (IC50 = 32 versus 45 microM).,Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997910/),μM,32,184268,DB00435,Nitric Oxide
,16997910,IC50,AcEGCG exhibited enhanced growth inhibitory activity relative to EGCG in both KYSE150 human esophageal (IC50 = 10 versus 20 microM) and HCT116 human colon cancer cells (IC50 = 32 versus 45 microM).,Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997910/),μM,45,184269,DB00435,Nitric Oxide
,16997910,area under the curve from 0 to infinity (AUC0-->infinity),"The plasma area under the curve from 0 to infinity (AUC0-->infinity) of total EGCG was 465.0 and 194.6 [(microg/ml) . min] from the administration of AcEGCG and EGCG, respectively.",Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997910/),[,465.0,184270,DB00435,Nitric Oxide
,16997910,area under the curve from 0 to infinity (AUC0-->infinity),"The plasma area under the curve from 0 to infinity (AUC0-->infinity) of total EGCG was 465.0 and 194.6 [(microg/ml) . min] from the administration of AcEGCG and EGCG, respectively.",Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997910/),[μg] / [min·ml)],194.6,184271,DB00435,Nitric Oxide
,16997910,t1/2,The t1/2 of EGCG was also increased following administration of AcEGCG compared with EGCG (441.0 versus 200.3 min).,Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997910/),min,441.0,184272,DB00435,Nitric Oxide
,16997910,t1/2,The t1/2 of EGCG was also increased following administration of AcEGCG compared with EGCG (441.0 versus 200.3 min).,Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997910/),min,200.3,184273,DB00435,Nitric Oxide
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB00435,Nitric Oxide
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB00435,Nitric Oxide
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB00435,Nitric Oxide
,15246088,BA,"In addition, ES-1537 had good pharmacokinetic profile in rats with BA value of 80%.","4,5-dialkylsubstituted 2-imino-1,3-thiazolidine derivatives as potent inducible nitric oxide synthase inhibitors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15246088/),%,80,187135,DB00435,Nitric Oxide
below,18779378,Plasma concentrations,Plasma concentrations declined below 1.0 microg/L within 30 minutes of cessation of infusion.,"Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779378/),[μg] / [l],1.0,192951,DB00435,Nitric Oxide
,23922746,ma,"There were no changes in mean systolic (SBP) and diastolic blood pressure (DBP) or other vital signs with L-arginine, although a transient but clinically unimportant mean maximal decrease in SBP of 14 mmHg was noted.","A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23922746/),,14,194174,DB00435,Nitric Oxide
,23922746,maximal,"No significant changes in mean potassium, glucose, bicarbonate, or pH were seen, with transient mean maximal increases in plasma potassium of 0.3 mmol/L, and mean maximal decreases in blood glucose of 0.8 mmol/L and bicarbonate of 2.3 mEq/L following L-arginine administration.","A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23922746/),[mM] / [l],0.8,194175,DB00435,Nitric Oxide
,23922746,maximal,"No significant changes in mean potassium, glucose, bicarbonate, or pH were seen, with transient mean maximal increases in plasma potassium of 0.3 mmol/L, and mean maximal decreases in blood glucose of 0.8 mmol/L and bicarbonate of 2.3 mEq/L following L-arginine administration.","A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23922746/),m,2,194176,DB00435,Nitric Oxide
,8930185,half-life,"A 24-hr pharmacokinetic analysis showed that AG was readily absorbed after i.p. administration, peaked in plasma (9.0 micrograms/ml) at 0.5 hr and had a half-life of 1.88 hr.",Pharmacokinetics of aminoguanidine administration and effects on the diabetes frequency in nonobese diabetic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930185/),h,1.88,194790,DB00435,Nitric Oxide
,8930185,area under the curve,"Steady-state values for the area under the curve for the therapeutic regimen were 20.51 and 16.35 (micrograms)(hr)/ml for the 0000 to 1600 and 1600 to 2400 hr, respectively.",Pharmacokinetics of aminoguanidine administration and effects on the diabetes frequency in nonobese diabetic mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930185/),[μgrams)(hr] / [ml],20.51,194791,DB00435,Nitric Oxide
,8930185,area under the curve,"Steady-state values for the area under the curve for the therapeutic regimen were 20.51 and 16.35 (micrograms)(hr)/ml for the 0000 to 1600 and 1600 to 2400 hr, respectively.",Pharmacokinetics of aminoguanidine administration and effects on the diabetes frequency in nonobese diabetic mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930185/),[μgrams)(hr] / [ml],16.35,194792,DB00435,Nitric Oxide
,8688264,nitric oxide uptake,"Mean nitric oxide uptake was 0.49 (SD 0.08) ml min-1 at standard temperature and pressure, corresponding to 74% of the inhaled dose.",Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688264/),[ml] / [min],0.49,195186,DB00435,Nitric Oxide
,8688264,time constant,"During inhalation, methaemoglobin increased monoexponentially with a time constant of 45.6 (11.1) min by 1.77 (0.47)% of total haemoglobin.",Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688264/),min,45.6,195187,DB00435,Nitric Oxide
,8688264,time constant,"Serum nitrogen oxides increased from 36.7 (7.6) to 124 (17) mumol litre-1, with a time constant of 172 (91.4) min and a volume of distribution of 331 (104) ml kg-1.",Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688264/),min,172,195188,DB00435,Nitric Oxide
,8688264,volume of distribution,"Serum nitrogen oxides increased from 36.7 (7.6) to 124 (17) mumol litre-1, with a time constant of 172 (91.4) min and a volume of distribution of 331 (104) ml kg-1.",Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688264/),[ml] / [kg],331,195189,DB00435,Nitric Oxide
,15781384,IC50,"Compound 30 has an IC50 of 60 nM for mouse iNOS and 185-fold and 9-fold selectivity for bovine eNOS and rat nNOS, respectively.","Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15781384/),nM,60,200340,DB00435,Nitric Oxide
,20634335,rate constant,"Our model revealed that nitrite entered erythrocytes rapidly with a rate constant of 0.256 min(-1) (i.e., half-life = 2.71 min).","Characterization of erythrocytic uptake and release and disposition pathways of nitrite, nitrate, methemoglobin, and iron-nitrosyl hemoglobin in the human circulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20634335/),1/[min],0.256,204478,DB00435,Nitric Oxide
,20634335,half-life,"Our model revealed that nitrite entered erythrocytes rapidly with a rate constant of 0.256 min(-1) (i.e., half-life = 2.71 min).","Characterization of erythrocytic uptake and release and disposition pathways of nitrite, nitrate, methemoglobin, and iron-nitrosyl hemoglobin in the human circulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20634335/),min,2.71,204479,DB00435,Nitric Oxide
,20634335,k,"The formation of iron-nitrosyl hemoglobin from nitrite, which involves the reduction of nitrite by deoxyhemoglobin to generate nitric oxide (NO) and reaction of NO with deoxyhemoglobin to form iron-nitrosyl hemoglobin, occurred rapidly as well (k = 2.02 min(-1); half-life = 0.343 min = 21 s).","Characterization of erythrocytic uptake and release and disposition pathways of nitrite, nitrate, methemoglobin, and iron-nitrosyl hemoglobin in the human circulation. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20634335/),1/[min],2.02,204480,DB00435,Nitric Oxide
,20634335,half-life,"The formation of iron-nitrosyl hemoglobin from nitrite, which involves the reduction of nitrite by deoxyhemoglobin to generate nitric oxide (NO) and reaction of NO with deoxyhemoglobin to form iron-nitrosyl hemoglobin, occurred rapidly as well (k = 2.02 min(-1); half-life = 0.343 min = 21 s).","Characterization of erythrocytic uptake and release and disposition pathways of nitrite, nitrate, methemoglobin, and iron-nitrosyl hemoglobin in the human circulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20634335/),min,0.343,204481,DB00435,Nitric Oxide
,20634335,half-life,"The formation of iron-nitrosyl hemoglobin from nitrite, which involves the reduction of nitrite by deoxyhemoglobin to generate nitric oxide (NO) and reaction of NO with deoxyhemoglobin to form iron-nitrosyl hemoglobin, occurred rapidly as well (k = 2.02 min(-1); half-life = 0.343 min = 21 s).","Characterization of erythrocytic uptake and release and disposition pathways of nitrite, nitrate, methemoglobin, and iron-nitrosyl hemoglobin in the human circulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20634335/),s,21,204482,DB00435,Nitric Oxide
,11918856,paO2/FiO2,"ARDS, induced after iv injection of endotoxin, was evidenced by reduction of paO2/FiO2 from (62.5 +/- 2.8) to (26 +/- 4) kPa and dynamic lung compliance (Cdyn) from (14.8 +/- 0.7) to (8.6 +/- 0.6) mL.kPa-1 .",Pharmacodynamics and pharmacokinetics of inhaled nitric oxide in dogs with septic acute respiratory distress syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918856/),kpa,62.5,207625,DB00435,Nitric Oxide
,11918856,paO2/FiO2,"ARDS, induced after iv injection of endotoxin, was evidenced by reduction of paO2/FiO2 from (62.5 +/- 2.8) to (26 +/- 4) kPa and dynamic lung compliance (Cdyn) from (14.8 +/- 0.7) to (8.6 +/- 0.6) mL.kPa-1 .",Pharmacodynamics and pharmacokinetics of inhaled nitric oxide in dogs with septic acute respiratory distress syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918856/),kpa,26,207626,DB00435,Nitric Oxide
,11918856,dynamic lung compliance (Cdyn),"ARDS, induced after iv injection of endotoxin, was evidenced by reduction of paO2/FiO2 from (62.5 +/- 2.8) to (26 +/- 4) kPa and dynamic lung compliance (Cdyn) from (14.8 +/- 0.7) to (8.6 +/- 0.6) mL.kPa-1 .",Pharmacodynamics and pharmacokinetics of inhaled nitric oxide in dogs with septic acute respiratory distress syndrome. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918856/),[ml] / [kpa],14.8,207627,DB00435,Nitric Oxide
,11918856,dynamic lung compliance (Cdyn),"ARDS, induced after iv injection of endotoxin, was evidenced by reduction of paO2/FiO2 from (62.5 +/- 2.8) to (26 +/- 4) kPa and dynamic lung compliance (Cdyn) from (14.8 +/- 0.7) to (8.6 +/- 0.6) mL.kPa-1 .",Pharmacodynamics and pharmacokinetics of inhaled nitric oxide in dogs with septic acute respiratory distress syndrome. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918856/),[ml] / [kpa],8.6,207628,DB00435,Nitric Oxide
,11918856,pulmonary vascular resistance index (PVRI),"kg-1, increase of dead space (VD/VT) from (0.14 +/- 0.06) to (0.58 +/- 0.05), intrapulmonary shunting (Qs/Qt) from 4.7 % +/- 1.7 % to 39 % +/- 7 %, and pulmonary vascular resistance index (PVRI) from (16 +/- 4) to (51 +/- 8) kPa.s.L-1 . m-2 (all P < 0.05), along with severe intrapulmonary neutrophil recruitment and peripheral neutropenia.",Pharmacodynamics and pharmacokinetics of inhaled nitric oxide in dogs with septic acute respiratory distress syndrome. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918856/),[kpa·s] / [(m)^2·l],16,207629,DB00435,Nitric Oxide
,11918856,pulmonary vascular resistance index (PVRI),"kg-1, increase of dead space (VD/VT) from (0.14 +/- 0.06) to (0.58 +/- 0.05), intrapulmonary shunting (Qs/Qt) from 4.7 % +/- 1.7 % to 39 % +/- 7 %, and pulmonary vascular resistance index (PVRI) from (16 +/- 4) to (51 +/- 8) kPa.s.L-1 . m-2 (all P < 0.05), along with severe intrapulmonary neutrophil recruitment and peripheral neutropenia.",Pharmacodynamics and pharmacokinetics of inhaled nitric oxide in dogs with septic acute respiratory distress syndrome. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918856/),[kpa·s] / [(m)^2·l],51,207630,DB00435,Nitric Oxide
,11918856,VD/VT,"iNO at 0.8, 1.6, and 3.2 micromol/L (20, 40, and 80 ppm) resulted in > 40 % increase of paO2/FiO2 and Cdyn, a reduction of VD/VT to 0.32, Qs/Qt to < 25 %, and PVRI by > 50 % (30.8 kPa . s . L-1 . m-2) compared to the control.",Pharmacodynamics and pharmacokinetics of inhaled nitric oxide in dogs with septic acute respiratory distress syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918856/),,0.32,207631,DB00435,Nitric Oxide
,25389223,IC50,"DNDI-VL-2098 (IC50 of 0.03 μM for the DD8 strain) showed excellent in vivo activity in both mouse and hamster models, with an ED90 value of 3.7 and <25 mg/kg, respectively, and was also found to be very effective against high-grade infection in the hamster model.",Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389223/),μM,0.03,214294,DB00435,Nitric Oxide
,25389223,ED90,"DNDI-VL-2098 (IC50 of 0.03 μM for the DD8 strain) showed excellent in vivo activity in both mouse and hamster models, with an ED90 value of 3.7 and <25 mg/kg, respectively, and was also found to be very effective against high-grade infection in the hamster model.",Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389223/),[mg] / [kg],3.7,214295,DB00435,Nitric Oxide
<,25389223,ED90,"DNDI-VL-2098 (IC50 of 0.03 μM for the DD8 strain) showed excellent in vivo activity in both mouse and hamster models, with an ED90 value of 3.7 and <25 mg/kg, respectively, and was also found to be very effective against high-grade infection in the hamster model.",Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389223/),[mg] / [kg],25,214296,DB00435,Nitric Oxide
,24185942,detection limit,"Here we show that a polyethylene glycol ligated copolymer stabilizes near-infrared-fluorescent single-walled carbon nanotubes sensors in solution, enabling intravenous injection into mice and the selective detection of local nitric oxide concentration with a detection limit of 1 µM.",In vivo biosensing via tissue-localizable near-infrared-fluorescent single-walled carbon nanotubes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24185942/),,1,214373,DB00435,Nitric Oxide
,24185942,half-life for liver retention,"The half-life for liver retention is 4 h, with sensors clearing the lungs within 2 h after injection, thus avoiding a dominant route of in vivo nanotoxicology.",In vivo biosensing via tissue-localizable near-infrared-fluorescent single-walled carbon nanotubes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24185942/),h,4,214374,DB00435,Nitric Oxide
,28099979,CL,The estimated value of CL is 7.65 mL/minute/3.4 kg (3.05 mL/minute/kg).,Milrinone Pharmacokinetics and Pharmacodynamics in Neonates with Persistent Pulmonary Hypertension of the Newborn. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28099979/),[ml] / [3.4·kg·min],7.65,214652,DB00435,Nitric Oxide
,28099979,CL,The estimated value of CL is 7.65 mL/minute/3.4 kg (3.05 mL/minute/kg).,Milrinone Pharmacokinetics and Pharmacodynamics in Neonates with Persistent Pulmonary Hypertension of the Newborn. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28099979/),[ml] / [kg·min],3.05,214653,DB00435,Nitric Oxide
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],233,217325,DB00435,Nitric Oxide
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],191,217326,DB00435,Nitric Oxide
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],242,217327,DB00435,Nitric Oxide
,9013401,CD50,"The CD50 value for aminophylline-induced clonus and tonus/ mortality was decreased from 233 to 191 and from 242 to 212 mg/kg, respectively.","NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013401/),[mg] / [kg],212,217328,DB00435,Nitric Oxide
,15207655,Tmax,"DA-8159 was absorbed rapidly with a Tmax of 0.6 hours in 30 mg/kg and 1.0 hour in the 10 mg/kg group, and T1/2 of 1.23 hours in 30 mg/kg and 1.17 hours in 10 mg/kg, respectively.",DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207655/),h,0.6,218213,DB00435,Nitric Oxide
,15207655,Tmax,"DA-8159 was absorbed rapidly with a Tmax of 0.6 hours in 30 mg/kg and 1.0 hour in the 10 mg/kg group, and T1/2 of 1.23 hours in 30 mg/kg and 1.17 hours in 10 mg/kg, respectively.",DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207655/),h,1.0,218214,DB00435,Nitric Oxide
,15207655,T1/2,"DA-8159 was absorbed rapidly with a Tmax of 0.6 hours in 30 mg/kg and 1.0 hour in the 10 mg/kg group, and T1/2 of 1.23 hours in 30 mg/kg and 1.17 hours in 10 mg/kg, respectively.",DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207655/),h,1.23,218215,DB00435,Nitric Oxide
,15207655,T1/2,"DA-8159 was absorbed rapidly with a Tmax of 0.6 hours in 30 mg/kg and 1.0 hour in the 10 mg/kg group, and T1/2 of 1.23 hours in 30 mg/kg and 1.17 hours in 10 mg/kg, respectively.",DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207655/),h,1.17,218216,DB00435,Nitric Oxide
,32144952,oral bioavailability,"Pharmacokinetic studies indicated that the oral bioavailability of AMF was 0.06 ± 0.04%, and the area under the curve of the glucuronidated AMF metabolites (410.938 ± 62.219 ng/ml h) was significantly higher than that of AMF (194.509 ± 16.915 ng/ml h).","Glucuronidation and its effect on the bioactivity of amentoflavone, a biflavonoid from Ginkgo biloba leaves. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32144952/),%,0.06,220984,DB00435,Nitric Oxide
,32144952,area under the curve,"Pharmacokinetic studies indicated that the oral bioavailability of AMF was 0.06 ± 0.04%, and the area under the curve of the glucuronidated AMF metabolites (410.938 ± 62.219 ng/ml h) was significantly higher than that of AMF (194.509 ± 16.915 ng/ml h).","Glucuronidation and its effect on the bioactivity of amentoflavone, a biflavonoid from Ginkgo biloba leaves. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32144952/),[ng] / [h·ml],410.938,220985,DB00435,Nitric Oxide
,32144952,area under the curve,"Pharmacokinetic studies indicated that the oral bioavailability of AMF was 0.06 ± 0.04%, and the area under the curve of the glucuronidated AMF metabolites (410.938 ± 62.219 ng/ml h) was significantly higher than that of AMF (194.509 ± 16.915 ng/ml h).","Glucuronidation and its effect on the bioactivity of amentoflavone, a biflavonoid from Ginkgo biloba leaves. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32144952/),[ng] / [h·ml],194.509,220986,DB00435,Nitric Oxide
,10232929,half-life of the elimination phase,"After a single bolus dose of 3-NT at 10 mg/kg, the average half-life of the elimination phase for the drug was 68.5+/-18.4 min (n = 5).",In vivo disposition of 3-nitro-L-tyrosine in rats: implications on tracking systemic peroxynitrite exposure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10232929/),min,68.5,221991,DB00435,Nitric Oxide
,10215749,plasma concentration,The mean baseline plasma concentration of L-arginine in the control study was 15.1+/-2.6 microg ml(-1).,Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215749/),[μg] / [ml],15.1,222284,DB00435,Nitric Oxide
,10215749,peak concentration,"The peak concentration after oral administration (10 g) was 50.0+/-13.4 microg ml(-1), occurring 1 h after administration.",Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215749/),[μg] / [ml],50.0,222285,DB00435,Nitric Oxide
,10215749,absolute bioavailability,The absolute bioavailability of a single oral 10 g dose of L-arginine is approximately 20%.,Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215749/),%,20,222286,DB00435,Nitric Oxide
,30703258,elimination half-life,Its mean elimination half-life was 0.7-2.5 hours.,A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703258/),h,0.7-2.5,226080,DB00435,Nitric Oxide
,28734159,m/z transitions,"We utilized multiple reaction monitoring (MRM) at m/z transitions of 306.2-164.0 to analyze CKD-712, and 340.3-202.1 m/z for IS, with a mobile phase of acetonitrile (0.025% trifluoroacetic acid):20mM ammonium acetate (94:6, v/v) at a flow rate of 0.25mL/min.",Development of a LC-MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28734159/),[m] / [z],306.2-164.0,226123,DB00435,Nitric Oxide
,28734159,m/z transitions,"We utilized multiple reaction monitoring (MRM) at m/z transitions of 306.2-164.0 to analyze CKD-712, and 340.3-202.1 m/z for IS, with a mobile phase of acetonitrile (0.025% trifluoroacetic acid):20mM ammonium acetate (94:6, v/v) at a flow rate of 0.25mL/min.",Development of a LC-MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28734159/),[m] / [z],340.3-202.1,226124,DB00435,Nitric Oxide
,28734159,flow rate,"We utilized multiple reaction monitoring (MRM) at m/z transitions of 306.2-164.0 to analyze CKD-712, and 340.3-202.1 m/z for IS, with a mobile phase of acetonitrile (0.025% trifluoroacetic acid):20mM ammonium acetate (94:6, v/v) at a flow rate of 0.25mL/min.",Development of a LC-MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28734159/),[ml] / [min],0.25,226125,DB00435,Nitric Oxide
,10870097,limit of sensitivity,The limit of sensitivity in plasma was 3.0 microM (0.75 microg mL(-1)).,Nonlinear pharmacokinetics of L-N(G)-methyl-arginine in rats: characterization by an improved HPLC assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870097/),μM,3.0,228315,DB00435,Nitric Oxide
,10870097,limit of sensitivity,The limit of sensitivity in plasma was 3.0 microM (0.75 microg mL(-1)).,Nonlinear pharmacokinetics of L-N(G)-methyl-arginine in rats: characterization by an improved HPLC assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870097/),[μg] / [ml],0.75,228316,DB00435,Nitric Oxide
,10870097,K(m),"From the nonlinear compartmental analysis, we estimated the K(m) and V(max) parameters of L-NMMA elimination to be 70.2 microM and 4.59 microM min(-1), respectively.",Nonlinear pharmacokinetics of L-N(G)-methyl-arginine in rats: characterization by an improved HPLC assay. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870097/),μM,70.2,228317,DB00435,Nitric Oxide
,10870097,V(max),"From the nonlinear compartmental analysis, we estimated the K(m) and V(max) parameters of L-NMMA elimination to be 70.2 microM and 4.59 microM min(-1), respectively.",Nonlinear pharmacokinetics of L-N(G)-methyl-arginine in rats: characterization by an improved HPLC assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870097/),[μM] / [min],4.59,228318,DB00435,Nitric Oxide
,10690516,systemic clearance,ONO-4007 has a low systemic clearance (approximately 1.3 ml/min) and a small volume of distribution (5-8 liters) with a long t1/2 of 74-95 h.,"Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690516/),[ml] / [min],1.3,230091,DB00435,Nitric Oxide
,10690516,volume of distribution,ONO-4007 has a low systemic clearance (approximately 1.3 ml/min) and a small volume of distribution (5-8 liters) with a long t1/2 of 74-95 h.,"Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690516/),l,5-8,230092,DB00435,Nitric Oxide
,10690516,t1/2,ONO-4007 has a low systemic clearance (approximately 1.3 ml/min) and a small volume of distribution (5-8 liters) with a long t1/2 of 74-95 h.,"Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690516/),h,74-95,230093,DB00435,Nitric Oxide
,31659803,terminal half-life,GB001 was well tolerated and rapidly absorbed with a 14.5-hour terminal half-life.,"A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31659803/),h,14.5,231466,DB00435,Nitric Oxide
,31659803,forced expiratory volume in 1 second,"Greater effects on forced expiratory volume in 1 second were observed in the high baseline fractional exhaled nitric oxide and blood eosinophil subgroups (207 mL [95% CI: -283, 698];133 mL [95% CI: -422, 687], respectively).","A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31659803/),ml,207,231467,DB00435,Nitric Oxide
,31659803,forced expiratory volume in 1 second,"Greater effects on forced expiratory volume in 1 second were observed in the high baseline fractional exhaled nitric oxide and blood eosinophil subgroups (207 mL [95% CI: -283, 698];133 mL [95% CI: -422, 687], respectively).","A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31659803/),ml,133,231468,DB00435,Nitric Oxide
,27927683,trough levels,"Pronounced elevations in trough levels of nitric oxide metabolites occurred with KNO3 (visit 2: 199.5, 95% CI 98.7-300.2 μmol/L; visit 3: 471.8, 95% CI 377.8-565.8 μmol/L) versus baseline (visit 1: 38.0, 95% CI 0.00-132.0 μmol/L; P<0.001).",Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27927683/),[μM] / [l],199.5,237991,DB00435,Nitric Oxide
,27927683,trough levels,"Pronounced elevations in trough levels of nitric oxide metabolites occurred with KNO3 (visit 2: 199.5, 95% CI 98.7-300.2 μmol/L; visit 3: 471.8, 95% CI 377.8-565.8 μmol/L) versus baseline (visit 1: 38.0, 95% CI 0.00-132.0 μmol/L; P<0.001).",Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27927683/),[μM] / [l],471.8,237992,DB00435,Nitric Oxide
,27927683,trough levels,"Pronounced elevations in trough levels of nitric oxide metabolites occurred with KNO3 (visit 2: 199.5, 95% CI 98.7-300.2 μmol/L; visit 3: 471.8, 95% CI 377.8-565.8 μmol/L) versus baseline (visit 1: 38.0, 95% CI 0.00-132.0 μmol/L; P<0.001).",Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27927683/),[μM] / [l],38.0,237993,DB00435,Nitric Oxide
,27927683,Peak nitric oxide metabolites concentrations,"Peak nitric oxide metabolites concentrations were 259.3 (95% CI 176.2-342.4) μmol/L 3.5 hours after ingestion, and the median half-life was 73.0 (interquartile range 33.4-232.0) minutes.",Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27927683/),[μM] / [l],259.3,237994,DB00435,Nitric Oxide
,27927683,half-life,"Peak nitric oxide metabolites concentrations were 259.3 (95% CI 176.2-342.4) μmol/L 3.5 hours after ingestion, and the median half-life was 73.0 (interquartile range 33.4-232.0) minutes.",Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27927683/),min,73.0,237995,DB00435,Nitric Oxide
,25556984,IC50,"This strategy, coupled with in silico modelling analysis, allowed for the identification of Cpd #15, an isoxazoline showing a sub-nanomolar inhibitory potency (IC50=0.84 nM) against TNFα-evoked IL-8 release in primary human airways smooth muscle cells.",Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556984/),nM,0.84,239539,DB00435,Nitric Oxide
,25556984,IC50,"In Raw264.7 mouse macrophages, Cpd #15 inhibited LPS-induced NO release with a potency (IC50=6 nM)>10-fold higher with respect to Dexamethasone.",Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556984/),nM,6,239540,DB00435,Nitric Oxide
,25556984,lung retention (t1/2,"Moreover, Cpd #15 proved to be suitable for pulmonary topical administration given its sustained lung retention (t1/2=6.5h) and high pulmonary levels (>100-fold higher than plasma levels) upon intratracheal administration in rats.",Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556984/),h,6.5,239541,DB00435,Nitric Oxide
,27281799,areas under the curve,Plasma oral arginine areas under the curve were lower after supplementation with SR-Arg than with IR-Arg (112 ± 52.3 and 142 ± 50.8 μmol ⋅ h/L; P < 0.01).,A Slow- Compared with a Fast-Release Form of Oral Arginine Increases Its Utilization for Nitric Oxide Synthesis in Overweight Adults with Cardiometabolic Risk Factors in a Randomized Controlled Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27281799/),[h·μM] / [l],112,239856,DB00435,Nitric Oxide
,27281799,areas under the curve,Plasma oral arginine areas under the curve were lower after supplementation with SR-Arg than with IR-Arg (112 ± 52.3 and 142 ± 50.8 μmol ⋅ h/L; P < 0.01).,A Slow- Compared with a Fast-Release Form of Oral Arginine Increases Its Utilization for Nitric Oxide Synthesis in Overweight Adults with Cardiometabolic Risk Factors in a Randomized Controlled Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27281799/),[h·μM] / [l],142,239857,DB00435,Nitric Oxide
>,15901348,volume of distribution (Vss,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),[l] / [kg],3.4,240319,DB00435,Nitric Oxide
,15901348,half-life (t1/2,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,7,240320,DB00435,Nitric Oxide
,15901348,plasma protein binding,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,0.1,240321,DB00435,Nitric Oxide
>,15901348,oral uptake,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,13,240322,DB00435,Nitric Oxide
,15901348,oral bioavailability,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,1.4,240323,DB00435,Nitric Oxide
,15901348,oral bioavailability,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,3.9,240324,DB00435,Nitric Oxide
,15901348,bioavailability (F),"Despite near-complete to complete uptake of the oral dose, AZD3582 administration resulted in a lower bioavailability (F) of total naproxen than naproxen administration: 55% and 85% relative bioavailability (Frel) in rats and minipigs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,55,240325,DB00435,Nitric Oxide
,15901348,bioavailability (F),"Despite near-complete to complete uptake of the oral dose, AZD3582 administration resulted in a lower bioavailability (F) of total naproxen than naproxen administration: 55% and 85% relative bioavailability (Frel) in rats and minipigs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,85,240326,DB00435,Nitric Oxide
,15901348,relative bioavailability (Frel),"Despite near-complete to complete uptake of the oral dose, AZD3582 administration resulted in a lower bioavailability (F) of total naproxen than naproxen administration: 55% and 85% relative bioavailability (Frel) in rats and minipigs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,85,240327,DB00435,Nitric Oxide
,15901348,t1/2,"Following dosing of AZD3582 or naproxen, the t1/2 of naproxen was 5, 9-10 and >40 h in rats, minipigs and dogs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,5,240328,DB00435,Nitric Oxide
,15901348,t1/2,"Following dosing of AZD3582 or naproxen, the t1/2 of naproxen was 5, 9-10 and >40 h in rats, minipigs and dogs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,9-10,240329,DB00435,Nitric Oxide
,15901348,t1/2,"Following dosing of AZD3582 or naproxen, the t1/2 of naproxen was 5, 9-10 and >40 h in rats, minipigs and dogs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,>,240330,DB00435,Nitric Oxide
,15901348,t1/2,"Following dosing of AZD3582 or naproxen, the t1/2 of naproxen was 5, 9-10 and >40 h in rats, minipigs and dogs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,40,240331,DB00435,Nitric Oxide
<,15778742,steady state K(d),"GW274150 and GW273629 are arginine competitive, NADPH-dependent inhibitors of human iNOS with steady state K(d) values of <40 and <90 nM, respectively.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),nM,40,241644,DB00435,Nitric Oxide
<,15778742,steady state K(d),"GW274150 and GW273629 are arginine competitive, NADPH-dependent inhibitors of human iNOS with steady state K(d) values of <40 and <90 nM, respectively.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),nM,90,241645,DB00435,Nitric Oxide
,15778742,IC(50),"2 GW274150 and GW273629 inhibited intracellular iNOS in J774 cells in a time-dependent manner, reaching IC(50) values of 0.2+/-0.04 and 1.3+/-0.16 microM, respectively.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),μM,0.2,241646,DB00435,Nitric Oxide
,15778742,IC(50),"2 GW274150 and GW273629 inhibited intracellular iNOS in J774 cells in a time-dependent manner, reaching IC(50) values of 0.2+/-0.04 and 1.3+/-0.16 microM, respectively.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),μM,1.3,241647,DB00435,Nitric Oxide
,15778742,terminal half-life,3 The pharmacokinetic profile of GW274150 was biphasic in healthy rats and mice with a terminal half-life of approximately 6 h.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),h,6,241648,DB00435,Nitric Oxide
,15778742,terminal half-life,"That of GW273629 was also biphasic in rats, producing a terminal half-life of approximately 3 h.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),h,3,241649,DB00435,Nitric Oxide
>,15778742,oral bioavailability,Both compounds show a high oral bioavailability (>90%) in rats and mice.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),%,90,241650,DB00435,Nitric Oxide
,15778742,ED(50),4 GW274150 was effective in inhibiting LPS-induced plasma NO(x) levels in mice with an ED(50) of 3.2+/-0.7 mg kg(-1) after 14 h intraperitoneally (i.p.) and 3.8+/-1.5 mg kg(-1) after 14 h when administered orally.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),[mg] / [kg],3.2,241651,DB00435,Nitric Oxide
,15778742,ED(50),4 GW274150 was effective in inhibiting LPS-induced plasma NO(x) levels in mice with an ED(50) of 3.2+/-0.7 mg kg(-1) after 14 h intraperitoneally (i.p.) and 3.8+/-1.5 mg kg(-1) after 14 h when administered orally.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),[mg] / [kg],3.8,241652,DB00435,Nitric Oxide
,15778742,ED(50),GW273629 showed shorter-lived effects on plasma NO(x) and an ED(50) of 9+/-2 mg kg(-1) after 2 h when administered i.p.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),[mg] / [kg],9,241653,DB00435,Nitric Oxide
,20171420,T(max),"The initial absorption phase of orally administered NXN-188 peaked at approximately 1 hour, followed by a second absorption phase with a T(max) of approximately 4 to 5 hours.","Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171420/),h,4 to 5,243185,DB00435,Nitric Oxide
,20171420,Clearance,"Clearance ranged from 70 to 130 L/h, and the NXN-188 halflife ranged from 11 to 178 hours.","Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171420/),[l] / [h],70 to 130,243186,DB00435,Nitric Oxide
,20171420,halflife,"Clearance ranged from 70 to 130 L/h, and the NXN-188 halflife ranged from 11 to 178 hours.","Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171420/),h,11 to 178,243187,DB00435,Nitric Oxide
,28160856,time to reach maximum concentration (Tmax),"Non-compartment pharmacokinetic analysis showed that the time to reach maximum concentration (Tmax) of plasma piperine after administration of piperine and STF were 3.9 and 1.7h, respectively.",Vasculoprotective and vasodilatation effects of herbal formula (Sahatsatara) and piperine in spontaneously hypertensive rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28160856/),h,3.9,245278,DB00435,Nitric Oxide
,28160856,time to reach maximum concentration (Tmax),"Non-compartment pharmacokinetic analysis showed that the time to reach maximum concentration (Tmax) of plasma piperine after administration of piperine and STF were 3.9 and 1.7h, respectively.",Vasculoprotective and vasodilatation effects of herbal formula (Sahatsatara) and piperine in spontaneously hypertensive rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28160856/),h,1.7,245279,DB00435,Nitric Oxide
,17901164,RBC,"Regardless of treatment, RBC citrulline was lower than plasma citrulline, with an RBC-to-plasma ratio of 0.60 +/- 0.04, and urinary citrulline excretion accounted for <1% of the citrulline load filtered by kidney.",Manipulation of citrulline availability in humans. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17901164/),,0.60,245640,DB00435,Nitric Oxide
,17901164,-to-plasma ratio,"Regardless of treatment, RBC citrulline was lower than plasma citrulline, with an RBC-to-plasma ratio of 0.60 +/- 0.04, and urinary citrulline excretion accounted for <1% of the citrulline load filtered by kidney.",Manipulation of citrulline availability in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17901164/),,0.60,245641,DB00435,Nitric Oxide
,9872349,sleep time,"Ethanol at a dose of 4 g/kg, i.p. induced sleep in rats (sleep time: 117.2+/-30.7 min).",The effects of the nitric oxide synthase inhibitor 7-nitroindazole on ethanol pharmacokinetics in rats after acute and chronic ethanol administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872349/),min,117.2,246861,DB00435,Nitric Oxide
,25923465,Rmax,"ACh-induced vasodilation was reduced in OVX rats as compared SHAM (Rmax: SHAM: 86±3.3 vs. OVX: 57±3.0%, p<0.01).",Aerobic Exercise Training Prevents the Onset of Endothelial Dysfunction via Increased Nitric Oxide Bioavailability and Reduced Reactive Oxygen Species in an Experimental Model of Menopause. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25923465/),%,86,249697,DB00435,Nitric Oxide
,25923465,Rmax,"ACh-induced vasodilation was reduced in OVX rats as compared SHAM (Rmax: SHAM: 86±3.3 vs. OVX: 57±3.0%, p<0.01).",Aerobic Exercise Training Prevents the Onset of Endothelial Dysfunction via Increased Nitric Oxide Bioavailability and Reduced Reactive Oxygen Species in an Experimental Model of Menopause. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25923465/),%,57,249698,DB00435,Nitric Oxide
,8743336,time to peak plasma drug concentration (tmax),The time to peak plasma drug concentration (tmax) is 1 to 2 hours.,Clinical pharmacokinetics of molsidomine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8743336/),h,1 to 2,249743,DB00435,Nitric Oxide
,8743336,bioavailability,"The bioavailability of the parent compound after oral administration in tablet form is 44 to 59%, but further metabolism to release NO and form polar metabolites is rapid; the half-life (t-1/2) of SIN-1 is 1 to 2 hours.",Clinical pharmacokinetics of molsidomine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8743336/),%,44 to 59,249744,DB00435,Nitric Oxide
,8743336,half-life (t-1/2),"The bioavailability of the parent compound after oral administration in tablet form is 44 to 59%, but further metabolism to release NO and form polar metabolites is rapid; the half-life (t-1/2) of SIN-1 is 1 to 2 hours.",Clinical pharmacokinetics of molsidomine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8743336/),h,1 to 2,249745,DB00435,Nitric Oxide
,8743336,Protein binding,Protein binding of the parent compound is very low (3 to 11%) and its volume of distribution (Vd) corresponds to the range of bodyweight.,Clinical pharmacokinetics of molsidomine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8743336/),%,3 to 11,249746,DB00435,Nitric Oxide
,9951425,clearance,"Median clearance of L-NG-methylarginine averaged 485 mL/h/kg for the 1 and 2.5 mg/kg/h dosing cohorts combined but decreased to 283, 181, and 98 mL/h/kg for the 5, 10, and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],485,250572,DB00435,Nitric Oxide
,9951425,clearance,"Median clearance of L-NG-methylarginine averaged 485 mL/h/kg for the 1 and 2.5 mg/kg/h dosing cohorts combined but decreased to 283, 181, and 98 mL/h/kg for the 5, 10, and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],283,250573,DB00435,Nitric Oxide
,9951425,clearance,"Median clearance of L-NG-methylarginine averaged 485 mL/h/kg for the 1 and 2.5 mg/kg/h dosing cohorts combined but decreased to 283, 181, and 98 mL/h/kg for the 5, 10, and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],181,250574,DB00435,Nitric Oxide
,9951425,clearance,"Median clearance of L-NG-methylarginine averaged 485 mL/h/kg for the 1 and 2.5 mg/kg/h dosing cohorts combined but decreased to 283, 181, and 98 mL/h/kg for the 5, 10, and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],98,250575,DB00435,Nitric Oxide
,9951425,renal clearance,"Median renal clearance was similar at 9 to 26 mL/h for the 1, 2.5, and 5 mg/kg/h dosing cohorts but increased to 156 and 284 mL/h for the 10 and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h],9 to,250576,DB00435,Nitric Oxide
,9951425,renal clearance,"Median renal clearance was similar at 9 to 26 mL/h for the 1, 2.5, and 5 mg/kg/h dosing cohorts but increased to 156 and 284 mL/h for the 10 and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h],26,250577,DB00435,Nitric Oxide
,9951425,renal clearance,"Median renal clearance was similar at 9 to 26 mL/h for the 1, 2.5, and 5 mg/kg/h dosing cohorts but increased to 156 and 284 mL/h for the 10 and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h],156,250578,DB00435,Nitric Oxide
,9951425,renal clearance,"Median renal clearance was similar at 9 to 26 mL/h for the 1, 2.5, and 5 mg/kg/h dosing cohorts but increased to 156 and 284 mL/h for the 10 and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h],284,250579,DB00435,Nitric Oxide
,9951425,steady-state volume of distribution,"Median steady-state volume of distribution was similar in all 5 dosing cohorts, averaging 0.66 to 0.82 L/kg.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[l] / [kg],0.66 to 0.82,250580,DB00435,Nitric Oxide
,9951425,clearance,"The 80% decrease in clearance from 485 to 98 mL/h/kg with the increase in dose suggests that a predominant metabolic pathway(s) of L-NG-methylarginine, accounting for at least 80% of clearance, is becoming progressively saturable in association with L-NG-methylarginine infusion rates > or = 5 mg/kg/h.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],485,250581,DB00435,Nitric Oxide
,9951425,clearance,"The 80% decrease in clearance from 485 to 98 mL/h/kg with the increase in dose suggests that a predominant metabolic pathway(s) of L-NG-methylarginine, accounting for at least 80% of clearance, is becoming progressively saturable in association with L-NG-methylarginine infusion rates > or = 5 mg/kg/h.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],98,250582,DB00435,Nitric Oxide
,15511691,half-life,"It is rapidly and completely absorbed and has a long half-life (63-69h in healthy volunteers) which allows twice-daily, or even once-daily, dosing.","Zonisamide: chemistry, mechanism of action, and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511691/),h,63-69,250903,DB00435,Nitric Oxide
,32279140,maximal concentration,"The maximal concentration of R-PhP in the brain tissues was 28 µg/g and 18 µg/g tissue after ip and po administration, respectively.",Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32279140/),[μg] / [g],28,252921,DB00435,Nitric Oxide
,32279140,maximal concentration,"The maximal concentration of R-PhP in the brain tissues was 28 µg/g and 18 µg/g tissue after ip and po administration, respectively.",Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32279140/),[μg] / [g],18,252922,DB00435,Nitric Oxide
,18716369,vascular peroxynitrite,The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups.,Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716369/),[pM] / [mg],1.6,254078,DB00435,Nitric Oxide
,18716369,concentration,The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups.,Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716369/),[pM] / [mg],1.6,254079,DB00435,Nitric Oxide
,11129076,retention time,The retention time of L-NIL was 19.4 min.,Determination of L-iminoethyl-L-lysine in serum by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11129076/),min,19.4,255715,DB00435,Nitric Oxide
,9860150,Cmax,Continuous intravenous infusion of 1 mg x kg(-1) x h(-1) of L-NAME for 12 h in patients with septic shock increased blood pressure and resulted in increasing plasma concentrations of L-NOARG (Cmax 6.2 microg x ml(-1) at 12 h) whereas L-NAME concentrations reached a plateau within 1.5 h (Cmax 1.0 microg x ml(-1)).,Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860150/),[μg] / [ml],6.2,258512,DB00435,Nitric Oxide
,9860150,Cmax,Continuous intravenous infusion of 1 mg x kg(-1) x h(-1) of L-NAME for 12 h in patients with septic shock increased blood pressure and resulted in increasing plasma concentrations of L-NOARG (Cmax 6.2 microg x ml(-1) at 12 h) whereas L-NAME concentrations reached a plateau within 1.5 h (Cmax 1.0 microg x ml(-1)).,Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860150/),[μg] / [ml],1.0,258513,DB00435,Nitric Oxide
,9860150,half-life,After the infusion was stopped L-NAME disappeared from the plasma rapidly (half-life 19.2 min) whereas L-NOARG concentration declined slowly (half-life 22.9 h).,Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860150/),min,19.2,258514,DB00435,Nitric Oxide
,9860150,half-life,After the infusion was stopped L-NAME disappeared from the plasma rapidly (half-life 19.2 min) whereas L-NOARG concentration declined slowly (half-life 22.9 h).,Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860150/),h,22.9,258515,DB00435,Nitric Oxide
,9860150,volume of distribution,The calculated volume of distribution for L-NAME was 0.451 x kg(-1) body weight and 1.961 x kg(-1) for L-NOARG.,Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860150/),1/[kg],0.451,258516,DB00435,Nitric Oxide
,9860150,volume of distribution,The calculated volume of distribution for L-NAME was 0.451 x kg(-1) body weight and 1.961 x kg(-1) for L-NOARG.,Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860150/),1/[kg],1.961,258517,DB00435,Nitric Oxide
,32322856,maximum value,"The cellular uptake of encapsulated resveratrol increased appreciably with observation time (1-4 h), reaching a maximum value (≈1.06 μg mL-1) after 2 h, whereas that of free resveratrol (in DMSO) only increased slightly, reaching 0.62 μg mL-1 after 4 h.",Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322856/),[μg] / [ml],1.06,259735,DB00435,Nitric Oxide
,32322856,maximum value,"The cellular uptake of encapsulated resveratrol increased appreciably with observation time (1-4 h), reaching a maximum value (≈1.06 μg mL-1) after 2 h, whereas that of free resveratrol (in DMSO) only increased slightly, reaching 0.62 μg mL-1 after 4 h.",Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322856/),[μg] / [ml],0.62,259736,DB00435,Nitric Oxide
,32322856,maximum,"The plasma level reached a maximum value of 1.35 ± 0.26 μg mL-1 at 4 h after feeding the En-RES formulation, and then decreased to 0.19 ± 0.04 μg mL-1 after 48 h.",Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322856/),[μg] / [ml],1.35,259737,DB00435,Nitric Oxide
,32322856,maximum,"Conversely, the plasma level only reached a maximum value of 0.31 ± 0.05 μg mL-1 at 0.5 h after feeding the free resveratrol formulation (an aqueous PEG 400 solution), and was totally cleared after 8 h.",Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322856/),[μg] / [ml],0.31,259738,DB00435,Nitric Oxide
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,2.6,263341,DB00435,Nitric Oxide
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,5.1,263342,DB00435,Nitric Oxide
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,7.01,263343,DB00435,Nitric Oxide
,27096084,absolute bioavailability,"To characterize the biopharmaceutical properties of riociguat, including absolute bioavailability, food interactions, and dose proportionality, riociguat (intravenous/oral) was administered to healthy male subjects in 3 open-label, randomized, crossover studies: absolute bioavailability (1 mg; [Formula: see text]), food effect (2.5 mg; [Formula: see text]), and dose proportionality (0.5-2.5 mg; [Formula: see text]).","Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27096084/),mg,1,263463,DB00435,Nitric Oxide
,27096084,Absolute bioavailability,"Absolute bioavailability was 94% (95% confidence interval [CI], 83%-107%).","Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27096084/),%,94,263464,DB00435,Nitric Oxide
,24306215,half-life,"A pharmacokinetic study with a single 2 μmol/kg oral administration showed a maximum 0.22 ± 0.02 μmol/L (n = 15) plasma concentration of indicaxanthin, with a half-life of 1.15 ± 0.11 h.",Indicaxanthin from cactus pear fruit exerts anti-inflammatory effects in carrageenin-induced rat pleurisy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24306215/),h,1.15,264275,DB00435,Nitric Oxide
,20843082,K(i),Biological evaluations have led to a nNOS inhibitor with a K(i) of 36 nM and high selectivity for nNOS over eNOS (3800-fold) and iNOS (1400-fold).,"Potent, highly selective, and orally bioavailable gem-difluorinated monocationic inhibitors of neuronal nitric oxide synthase. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20843082/),nM,36,267319,DB00435,Nitric Oxide
,20843082,oral bioavailability,A comparison of rat oral bioavailability of the difluorinated compound to the parent molecule shows 22% for the difluorinated compound versus essentially no oral bioavailability for the parent compound.,"Potent, highly selective, and orally bioavailable gem-difluorinated monocationic inhibitors of neuronal nitric oxide synthase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20843082/),%,22,267320,DB00435,Nitric Oxide
,28843617,clearance (CL),"Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day-1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%).",Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28843617/),[l] / [d],0.156,269449,DB00435,Nitric Oxide
,28843617,central volume (Vc),"Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day-1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%).",Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28843617/),l,4.10,269450,DB00435,Nitric Oxide
,28843617,absorption rate (ka),"Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day-1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%).",Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28843617/),1/[d],0.239,269451,DB00435,Nitric Oxide
,28843617,bioavailability,"Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day-1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%).",Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28843617/),%,85.6,269452,DB00435,Nitric Oxide
,28843617,CL,"Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day-1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%).",Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28843617/),%,33.3,269453,DB00435,Nitric Oxide
,28843617,Vc,"Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day-1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%).",Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28843617/),%,36.3,269454,DB00435,Nitric Oxide
,28843617,ka,"Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day-1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%).",Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28843617/),%,40.8,269455,DB00435,Nitric Oxide
,28843617,terminal half-life,The estimated mean terminal half-life was 25.7 days.,Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28843617/),d,25.7,269456,DB00435,Nitric Oxide
,25764208,half-life,Single-dose intravenous and subcutaneous pharmacokinetics studies indicate that ABT-981 has a half-life of 8.0 to 10.4 d in cynomolgus monkey and 10.0 to 20.3 d in rodents.,"Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25764208/),d,8.0 to 10.4,270110,DB00435,Nitric Oxide
,25764208,half-life,Single-dose intravenous and subcutaneous pharmacokinetics studies indicate that ABT-981 has a half-life of 8.0 to 10.4 d in cynomolgus monkey and 10.0 to 20.3 d in rodents.,"Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25764208/),d,10.0 to 20.3,270111,DB00435,Nitric Oxide
,20421938,ADMA,Plasma ADMA was increased in SM patients (0.85 microM; 95% CI 0.74-0.96) compared to those with MSM (0.54 microM; 95%CI 0.5-0.56) and HCs (0.64 microM; 95%CI 0.58-0.70; p<0.001).,Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20421938/),μM,0.85,273118,DB00435,Nitric Oxide
,20421938,ADMA,Plasma ADMA was increased in SM patients (0.85 microM; 95% CI 0.74-0.96) compared to those with MSM (0.54 microM; 95%CI 0.5-0.56) and HCs (0.64 microM; 95%CI 0.58-0.70; p<0.001).,Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20421938/),μM,0.54,273119,DB00435,Nitric Oxide
,20421938,ADMA,Plasma ADMA was increased in SM patients (0.85 microM; 95% CI 0.74-0.96) compared to those with MSM (0.54 microM; 95%CI 0.5-0.56) and HCs (0.64 microM; 95%CI 0.58-0.70; p<0.001).,Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20421938/),μM,0.64,273120,DB00435,Nitric Oxide
